camptothecin has been researched along with Carcinoma, Non-Small Cell Lung in 401 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 84 (20.95) | 18.2507 |
| 2000's | 217 (54.11) | 29.6817 |
| 2010's | 79 (19.70) | 24.3611 |
| 2020's | 21 (5.24) | 2.80 |
| Authors | Studies |
|---|---|
| Furbacher, TR; Gunatilaka, AA | 1 |
| Chen, YL; Chen, YW; Liang, CC; Lu, PJ; Tseng, CH; Tzeng, CC; Yang, CN; Yao, YC | 1 |
| Acharyya, S; Bazhenova, L; Cheng, Y; Felip, E; Goto, Y; Jänne, PA; Li, BT; Mazières, J; Nagasaka, M; Nakagawa, K; Pacheco, JM; Paz-Ares, L; Pérol, M; Planchard, D; Saltos, AN; Saxena, K; Shahidi, J; Shiga, R; Smit, EF; Udagawa, H; Vitazka, P | 1 |
| Cho, BC; Kim, CG; Lee, JB; Lim, SM | 1 |
| O'Rourke, K | 1 |
| Costa, DB; Rangachari, D; Viray, H | 1 |
| Jänne, PA; Li, BT; Smit, EF | 1 |
| Louie, AV; Mak, RH; Tjong, MC | 1 |
| Abuhelwa, Z; Alloghbi, A; Alqahtani, A; Nagasaka, M | 1 |
| Chen, BH; Chiu, CC; Chou, CK; Chou, HL; Hung, CT; Tsai, EM; Urade, R; Wang, TN; Wu, SJ | 1 |
| Dy, GK; Gupta, A; Gupta, K; Jatwani, K; Qiu, J | 1 |
| Domańska, I; Laskowska, A; Oledzka, E; Paśnik, K; Piotrowska, U; Sobczak, M; Szeleszczuk, Ł; Zielińska-Pisklak, M | 1 |
| Bazhenova, L; Yun, KM | 1 |
| Chen, H; Liu, C; Qiao, W; Shafiq, F; Yu, S; Zhou, H | 1 |
| Abel, ML; Aladjem, M; Butcher, D; Del Rivero, J; Desai, P; Figg, WD; Goyal, S; Graham, C; Karim, B; Kattappuram, R; Kim, J; Krishnamurthy, M; Kumar, R; Lee, MJ; Lee, S; Malin, J; Nichols, S; Peer, C; Pinkiert, D; Pommier, Y; Raffeld, M; Redon, CE; Schroeder, B; Schultz, CW; Sciuto, L; Sharma, AK; Shelat, M; Sissung, T; Takahashi, N; Thomas, A; Trepel, J; Tyagi, M; Upadhyay, D; Vilimas, R; Xi, L | 1 |
| Barlesi, F; Gazzah, A; Mahjoubi, L; Parisi, C | 1 |
| Hoe, HJ; Solomon, BJ | 1 |
| Ahn, MJ; Cheng, FC; Cheng, Y; de Langen, AJ; Feng, W; Goto, K; Goto, Y; Hayashi, H; Jänne, PA; Kim, DW; Kim, SW; Kubo, T; Kuo, CH; Ninomiya, K; Novello, S; Pereira, K; Pérol, M; Planchard, D; Pons-Tostivint, E; Shimizu, J; Smit, EF; Taguchi, A; Tsuchihashi, Z; Yang, JC | 1 |
| Bai, L; Chen, L; Guo, C; Guo, D; Jiang, P; Jiang, Z; Shi, J; Tong, R; Xu, Z; Yu, D; Zhu, Y | 1 |
| Chi, Y; Dai, G; Feng, F; Liu, J; Wu, C; Xu, K; Zhong, W | 1 |
| Cortés, J; Garrigós, L; Gion, M; Jänne, PA; Perez, J; Shitara, K; Siena, S | 1 |
| Abnous, K; Alibolandi, M; Ramezani, M; Shahriari, M; Taghdisi, SM | 1 |
| Deneka, AY; Gaponova, AV; Golemis, EA; Haber, L; Kopp, MC; Nikonova, AS | 1 |
| Bardia, A; Berlin, J; Camidge, DR; Goldenberg, DM; Govindan, SV; Guarino, MJ; Heist, RS; Horn, L; Maliakal, P; Masters, G; Messersmith, WA; Mudenda, B; Ocean, AJ; Purcell, WT; Scheff, RJ; Sharkey, RM; Starodub, AN; Wegener, WA | 1 |
| Blaydorn, L; Coats, J; Farley, JH; Khemka, V; Lynch, CA; McGahey, K; Niu, J; Sangal, A; Waypa, J; Weiss, GJ | 1 |
| Arrieta, O; Cardona, AF; Carranza, H; Corrales, L; Cuello, M; Martín, C; Otero, J; Pino, LE; Reguart, N; Rojas, L; Rolfo, C; Rosell, R; Ruiz-Patiño, A; Vargas, C; Wills, B; Zatarain-Barrón, ZL | 1 |
| Cao, L; Cheng, K; Su, Q; Zhang, X; Zhang, Y | 1 |
| Li, L; Wang, S; Xu, C; Yang, D; Yang, J; Yuan, S | 1 |
| Chen, BH; Chen, JY; Chiu, CC; Chiu, YH; Hsu, HW; Hsu, SH; Huang, KC; Huang, WP; Liu, W; Wu, CY | 1 |
| Hong, T; Li, J; Liu, W; Luo, J; Tong, L; Wang, F; Yan, L; Yang, X; Zhou, Y | 1 |
| Fukuhara, T; Inoue, A; Ishimoto, O; Maemondo, M; Matsubara, N; Morikawa, N; Nukiwa, T; Sakakibara, T; Sugawara, S; Tanaka, M; Watanabe, K | 1 |
| Choi, DR; Choi, HC; Kim, B; Kim, HS; Kim, JH; Kwon, JH | 1 |
| Ishii, G; Ishikawa, Y; Kenmotsu, H; Nagai, K; Nakajima, R; Niho, S; Noguchi, M; Oshita, F; Sekine, I; Tada, H; Watanabe, S | 1 |
| Gao, D; Ibrahim, S; Sinko, PJ | 1 |
| Kondo, T; Murakami, S; Oshita, F; Saito, H; Yamada, K | 2 |
| Arce-Lara, C; Kelley, MJ; Santana-Davila, R; Szabo, A; Whittle, J; Williams, CD | 1 |
| Adane, ED; Arnold, SM; Leggas, M; Liang, Y; Tsakalozou, E | 1 |
| Cheng, L; Jia, J; Li, Q; Tu, L; Wang, X; Yan, D; Zheng, X | 1 |
| Baylin, SB; Dobromilskaya, I; Easwaran, H; Huang, P; Poirier, JT; Rudin, CM; Topper, M; Vendetti, FP; Wrangle, J | 1 |
| Arai, D; Betsuyaku, T; Ikemura, S; Ishioka, K; Kabata, H; Kamata, H; Kawada, I; Miyata, J; Naoki, K; Ohgino, K; Sato, T; Soejima, K; Terai, H; Yasuda, H; Yoda, S | 1 |
| Del Rio, M; Gongora, C; Jin, C; Lam, H; Li, F; Ling, X; Wani, M; Welch, J; Westover, D | 1 |
| Gjerset, RA; Zhao, M | 1 |
| Aherne, GW; Box, G; Boxall, KJ; Collins, I; De Haven Brandon, AK; Eccles, SA; Eve, PD; Garrett, MD; Hayes, A; Henley, AT; Hunter, JE; Lainchbury, M; Matthews, TP; McHardy, T; Osborne, J; Perkins, ND; Raynaud, FI; Reader, JC; Swales, K; Tall, M; Valenti, MR; Walton, MI | 1 |
| Chen, L; Cheng, X; Liu, H; Qiu, N; Wang, W; Wang, Z; Wen, J; Yang, J | 1 |
| Hur, GY; Kang, EJ; Kang, KH; Kim, JS; Lee, SY; Min, KH; Oh, SC; Seo, JH; Shim, JJ | 1 |
| Li, CY; Wang, D; Xu, MF; Yang, XQ; Zhao, H | 1 |
| Chen, X; Dai, L; Fang, J; Han, J; Han, S; Hu, W; Long, J; Ma, X; Nie, J; Tian, G; Wang, Y; Wu, D; Zhang, J | 1 |
| Chang, WT; Chen, JY; Chiu, CC; Chou, HL; Fong, Y; Huang, HW; Tsai, EM; Wei, CK; Wu, CY | 1 |
| Chang, WT; Chen, JY; Chiu, CC; Chou, HL; David Wang, HM; Fong, Y; Huang, HW; Lin, HH; Tsai, EM; Wu, CY | 1 |
| Fan, WF; Meng, LJ; Pu, XL; Wang, J; Yang, M | 1 |
| Chisaki, Y; Nakamura, N; Yano, Y | 1 |
| An, HJ; Han, JY; Kim, HT; Lee, GK; Lee, JS; Lee, Y; Lim, KY; Moon, SH; Nam, BH; Yun, T | 1 |
| Davies, A; Gandara, D; Huynh, M; Johl, J; Lara, P; Lau, D; Tanaka, M | 1 |
| Creaven, PJ; Gottlieb, RH; Iyer, RV; Khushalani, NI; Ramnath, N; Rustum, YM; Schwarz, JK; Yu, J | 1 |
| Eguchi, K; Isobe, H; Kunikane, H; Masuda, N; Ogura, T; Shibuya, M; Takahashi, T; Takeda, Y; Watanabe, K; Yamamoto, N; Yokoyama, A | 1 |
| Ebi, N; Fukuoka, M; Katakami, N; Kubo, A; Miyazaki, M; Nakagawa, K; Nishimura, T; Okamoto, I; Sugawara, S; Takeda, K; Yoshioka, H | 1 |
| Baki, M | 1 |
| Ahn, JS; Ahn, MJ; Chang, MH; Hwang, IG; Ji, SH; Jun, HJ; Kim, HS; Kim, KH; Lee, J; Lim, DH; Park, K; Park, MJ; Park, YH; Uhm, JE; Yi, SY | 1 |
| Honda, Y; Ishida, T; Ishimoto, O; Munakata, M; Sugawara, S | 1 |
| Fujimoto, T; Koshiji, M; Nambu, Y; Yamamoto, N | 1 |
| Frese, S; Frese-Schaper, M; Gugger, M; Schmid, RA; Schüller, A | 1 |
| Endo, M; Igawa, S; Ito, I; Kaira, K; Kameya, T; Murakami, H; Naito, T; Nakamura, Y; Takahashi, T; Tsuya, A; Watanabe, R; Yamamoto, N | 1 |
| He, Q; Lou, J; Lu, W; Yang, B; Yang, X; Zhang, C; Zhu, D; Zhu, H | 1 |
| Harada, M; Isobe, H; Izumi, K; Mino, K; Saito, K; Tanaka, H | 1 |
| Fujii, T; Fukuda, H; Kunikane, H; Kunitoh, H; Mori, K; Okamoto, H; Saijo, N; Tamura, T; Watanabe, K; Yokoyama, A | 1 |
| Abdel Karim, N; Flora, D; Gupta, A; Issa, M; Jazieh, AR; Knapp, M; Komrokji, R; Patil, S | 1 |
| Cho, EY; Han, JY; Kim, HT; Lee, GK; Lee, JS; Yoo, SY; Yoon, SJ | 1 |
| Han, N; Liu, ZW; Wang, J; Zhang, ZM | 1 |
| Goto, K; Kenmotsu, H; Koga, Y; Kuroda, J; Matsumura, Y; Nagano, T; Nishimura, Y; Nishiwaki, Y; Sugino, T; Yasunaga, M | 1 |
| Fujimoto, N; Fujiwara, Y; Kiura, K; Tabata, M; Takigawa, N; Tanimoto, M; Toyooka, S; Ueoka, H; Umemura, S | 1 |
| Bastos, BR; Gomez, J; Hatoum, GF; Lopes, G; Raez, LE; Santos, ES; Takita, C; Tolba, K; Walker, GR | 1 |
| Adachi, M; Hirose, T; Kusumoto, S; Ohmori, T; Ohnishi, T; Okuda, K; Shirai, T; Sugiyama, T; Yamaoka, T | 1 |
| Huang, G; Wang, H; Yang, LX | 1 |
| Choi, JY; Han, JY; Kim, JY; Park, IH | 1 |
| Fukuoka, M; Komiya, T; Kurata, T; Miyazaki, M; Nakagawa, K; Takeda, K; Tamura, K; Tsurutani, J; Yamamoto, N | 1 |
| Hatch, H; Hirai, H; Kotani, H; Majumder, PK; Miyama, K; Nakatsuru, Y; Pan, BS; Sootome, H; Taguchi, S; Tsujioka, K; Ueno, Y | 1 |
| Chiba, Y; Fukuoka, M; Hida, T; Imamura, F; Iwamoto, Y; Katakami, N; Kawahara, M; Kudo, S; Nakagawa, K; Nishimura, Y; Saka, H; Satouchi, M; Sawa, T; Semba, H; Seto, T; Takeda, K; Tsujino, K; Uejima, H; Yamamoto, N; Yokota, S | 1 |
| Kalinowska-Lis, U; Kontek, R; Marciniak, B; Matlawska-Wasowska, K | 1 |
| Aoe, K; Hayashi, H; Hotta, K; Kawai, H; Kiura, K; Maeda, T; Matsuo, K; Segawa, Y; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H; Yoshioka, H | 1 |
| Fukuda, H; Fukuoka, M; Kawahara, M; Kudoh, S; Nakagawa, K; Negoro, S; Saijo, N; Sawa, T; Semba, H; Takeda, K; Tanaka, M | 1 |
| Jaitner, S; Jung, A; Kirchner, T; Schäffauer, AJ | 1 |
| Honda, T; Kondo, T; Murakami, S; Nakayama, Y; Noda, K; Ohe, M; Oshita, F; Saito, H; Yamada, K; Yamashita, K | 1 |
| Ikeda, S; Inagaki, M; Suzuki, K; Takabe, K | 1 |
| Hirami, Y; Maeda, A; Nakata, M; Oka, M; Shimizu, K; Tanemoto, K; Yukawa, T | 1 |
| Agelaki, S; Androulakis, N; Bozionelou, V; Georgoulias, V; Hatzidaki, D; Kalbakis, K; Kalykaki, A; Kotsakis, A; Saridaki, Z; Vamvakas, L; Vardakis, N | 1 |
| Fukuda, M; Kasai, T; Kinoshita, A; Kohno, S; Masuda, N; Nagashima, S; Nakamura, Y; Nakatomi, K; Oka, M; Soda, H; Soejima, Y; Takatani, H; Tsukamoto, K | 1 |
| Honda, T; Kondo, T; Murakami, S; Noda, K; Oshita, F; Saito, H; Yamada, K | 1 |
| Asano, K; Ikemura, S; Kawada, I; Morosawa, M; Nakachi, I; Nakayama, S; Naoki, K; Sato, T; Satomi, R; Soejima, K; Terai, H; Watanabe, H; Yasuda, H; Yoda, S | 1 |
| Huang, XE; Li, C; Li, Y | 1 |
| Ayuzawa, R; Doi, C; Maurya, DK; Tamura, M; Troyer, D | 1 |
| Chen, Y; Hotta, K; Ichihara, E; Kiura, K; Ochi, N; Tabata, M; Takigawa, N; Tanimoto, M; Tanimoto, Y; Zhang, D | 1 |
| Ariyoshi, Y; Fukuoka, M; Kakihata, K; Masatani, S; Sakata, Y; Shimazaki, M; Shiozawa, T; Tadokoro, J; Yamaguchi, F | 1 |
| Horai, T; Horiike, A; Kasahara, K; Kudo, K; Miyauchi, E; Nishio, M; Ohyanagi, F | 1 |
| Akie, K; Dosaka-Akita, H; Fujita, Y; Fukumoto, S; Harada, M; Harada, T; Isobe, H; Kikuchi, E; Kinoshita, I; Kojima, T; Nishimura, M; Ogura, S; Ohsaki, Y; Oizumi, S; Shinagawa, N | 1 |
| Cai, JF; Chen, B; Lu, HY; Ma, SL; Su, D; Sun, WY; Wang, Z; Zhang, YP; Zheng, YQ | 1 |
| Belinsky, SA; Bernauer, AM; Dacic, S; Dahlberg, SE; Klinge, DM; Liu, Y; Schiller, JH; Siegfried, JM; Tessema, M; Thomas, CL; Yingling, CM | 1 |
| Fujimoto-Ouchi, K; Iwai, T; Mori, K; Moriya, Y; Shirane, M | 1 |
| Gaya, A; Tse, V | 1 |
| Fujii, M; Hamada, N; Hosokawa, S; Hotta, K; Ichihara, E; Ikeda, G; Kiura, K; Kuyama, S; Nogami, N; Osawa, M; Oze, I; Segawa, Y; Shibayama, T; Tabata, M; Tada, A; Takata, S; Takigawa, N; Tamaoki, A; Tanimoto, M; Uno, M | 1 |
| Iyoda, A; Jiang, SX; Kageyama, T; Masuda, N; Matsumoto, T; Nagashio, R; Ryuge, S; Saegusa, M; Sato, Y; Satoh, Y | 1 |
| Ghang, HY; Han, JY; Hwang, JA; Kim, JY; Kim, SY; Lee, JS; Lee, YS; Shin, ES | 1 |
| Fujimura, M; Kasahara, K; Kimura, H; Nakao, S; Ohmori, T; Sakai, A; Sone, T | 1 |
| Han, JY; Kim, HT; Kim, HY; Lee, JS; Nam, BH; Yoon, SJ | 1 |
| Chang, H; Cho, BC; Kim, HR; Kim, JH; Kim, SH; Lee, CG; Yoon, SH | 1 |
| Agatsuma, T; Goya, H; Hirai, K; Ichiyama, T; Kanda, S; Koizumi, T; Koyama, S; Kubo, K; Kuraishi, H; Tateishi, K; Yamamoto, H; Yoshiike, F | 1 |
| Date, H; Hotta, K; Kanazawa, S; Katsui, K; Kiura, K; Miyoshi, S; Shien, K; Toyooka, S | 1 |
| Antonelli, G; Blandino, R; Calì, S; Ferraù, F; Malaponte, E; Panebianco, V; Vitale, FV | 1 |
| Kontek, R; Nowicka, H | 1 |
| Chen, DY; Zhao, WY | 1 |
| Behera, D; Das, A; Madan, K; Singh, N | 1 |
| Abad, A; Barnadas, A; Font, A; Guillot, M; Manzano, JL; Margeli, M; Martinez, E; Rosell, R; Sanchez, JM; Taron, M | 1 |
| Akiyama, Y; Handa, S; Kobayashi, K; Kudo, K; Kudoh, S; Soma, T; Takeda, Y | 1 |
| Green, MR | 2 |
| Fukuda, H; Fukuoka, M; Kudoh, S; Nakagawa, K; Negoro, S; Nishimura, Y; Takeda, K; Tanaka, M; Yamada, M; Yamamoto, N | 1 |
| Fukuda, M; Kasai, T; Kawabata, S; Kinoshita, A; Kohno, S; Nagashima, S; Nakamura, Y; Nakatomi, K; Oka, M; Soda, H; Takatani, H; Tsurutani, J | 1 |
| Bunn, PA | 2 |
| Antonellini, A; Elfring, GL; Gillenwater, HH; Israel, VK; Locker, PK; Miller, LL; Natale, RB; Sandler, AB; Socinski, MA | 1 |
| Ichinose, Y | 1 |
| Choy, H; Wu, HG | 1 |
| Kelly, K | 1 |
| Algarra, SM; Aramendía, JM; Aristu, J; Brugarolas, A; González Cao, M; Martínez Monje, R; Ordoñez, JM; Salgado, E | 1 |
| Harper, P; Marx, G | 1 |
| Negoro, S; Takeda, K; Takifuji, N; Terakawa, K; Uejima, H; Yoshimura, N | 1 |
| Douillard, JY; Eckardt, J; Scagliotti, GV | 1 |
| Fossella, F; Milas, L; Rosell, R | 1 |
| Ariyoshi, Y; Fukuoka, M; Katakami, N; Kudoh, S; Masuda, N; Negoro, S; Niitani, H; Ohashi, Y; Sugiura, T; Takada, Y | 1 |
| Artal, A; Balcells, M; Barneto, I; Cardenal, F; Carrato, A; Domine, M; Felip, E; Garrido, P; Juan, O; López-Vivanco, G; Massutí, B; Rosell, R | 1 |
| Hiroi, M; Hojyo, T; Isobe, K; Kimura, K; Ryo, H; Sano, G; Sugino, K; Toyama, K; Yamada, H | 1 |
| Eguchi, K; Goto, K; Hojo, F; Kakinuma, R; Kodama, T; Kubota, K; Kunitoh, H; Matsumoto, T; Nishiwaki, Y; Ohe, Y; Ohmatsu, H; Saijo, N; Sekine, I; Shinkai, T; Tamura, T; Yoshimura, K | 1 |
| Fujiwara, K; Hamasaki, S; Kiura, K; Tabata, M; Tanimoto, M; Ueoka, H | 1 |
| Kamiyama, Y; Kano, Y; Kondo, T; Mori, K; Tominaga, K | 1 |
| Ikehara, M; Kato, Y; Noda, K; Nomura, I; Oshita, F; Saito, H; Suzuki, R; Tanaka, G; Yamada, K | 1 |
| Aizawa, H; Gohara, R; Ichiki, M; Kamimura, T; Kawayama, T; Koga, T; Matunami, M; Oshita, Y; Rikimaru, T | 1 |
| Pizzolato, JF; Saltz, LB | 1 |
| Kosmidis, PA; Manegold, C | 1 |
| Braybrooke, JP; Cheverton, P; Manegold, C; Mattson, K; Oyama, R; Ranson, M; Sekiguchi, M; Suzuki, M; Talbot, DC; Thatcher, N | 1 |
| Faust, J; Govindan, R; Mc Leod, H; Read, W | 1 |
| Abe, S; Fujita, A; Hoshino, H; Ohkubo, T; Sekine, K; Tagaki, S; Takabatake, H | 1 |
| Botti, G; Capasso, I; Comella, G; Comella, P; D'Aiuto, G; De Rosa, V; Di Bonito, M; Frasci, G; Lapenta, L; Thomas, R; Vallone, P | 1 |
| De Cesare, M; Giordano, V; Laccabue, D; Lanzi, C; Marcellini, M; Petrangolini, G; Pisano, C; Pratesi, G; Supino, R; Zunino, F | 1 |
| Evans, SS; Harper, SM; Nagourney, RA; Radecki, S; Sommers, BL | 1 |
| Abad, A; Barnadas, A; Font, A; Manzano, JL; Margelí, M; Martinez-Balibrea, E; Richardet, M; Rosell, R; Sánchez, JJ; Sánchez, JM; Tarón, M | 1 |
| Blay, P; Buesa, JM; Esteban, E; Estrada, E; Fernández, Y; Fra, J; Lacave, AJ; Mareque, B; Muñiz, I; Palacio, I; Sánchez, R; Uña, E; Vieitez, JM; Villanueva, N | 1 |
| Eguchi, K; Kobayashi, K; Matsumoto, T; Morita, S; Ohashi, Y; Sakamoto, J; Shibuya, M; Yamaji, Y | 1 |
| Broggini, M; Colombo, T; Geroni, C; Marchini, S; Sabatino, MA | 1 |
| Han, JY; Ju, SY; Kim, EA; Kim, HY; Lee, DH; Lee, JJ; Lee, JS; Shin, EH | 1 |
| Ariyoshi, Y; Fukuoka, M; Hoso, T; Katakami, N; Kawahara, M; Kudoh, S; Matsui, K; Nakagawa, K; Nakano, T; Negoro, SI; Saito, H; Senba, H; Sugiura, T; Takada, Y; Yamamoto, N | 1 |
| Pan, XD; Wang, CY | 1 |
| Bradbury, DA; Brea-Calvo, G; Knox, AJ; Navas, P; Sánchez-Alcázar, JA | 1 |
| Crawford, J; Govindan, R; Green, MR; Herndon, JE; King, GW; Rizvi, NA; Rocha Lima, CM; Zhang, C | 1 |
| Du, GZ; Gao, JF; Li, CS; Ou, WL; Wang, J; Yang, B; Zhang, BC; Zhang, XH; Zhu, YZ | 1 |
| Ikehara, M; Noda, K; Nomura, I; Oshita, F; Tanaka, G; Yamada, K | 1 |
| Fujiwara, K; Hisamoto, A; Hosokawa, S; Hotta, K; Kiura, K; Kozuki, T; Kuyama, S; Satoh, K; Tabata, M; Tanimoto, M; Ueoka, H | 1 |
| Gemba, K; Harita, S; Kamei, H; Kiura, K; Nogami, N; Segawa, Y; Tabata, M; Tanimoto, M; Ueoka, H; Yonei, T | 1 |
| Raez, LE; Reis, IM; Rosado, MF; Santos, ES | 1 |
| Adams, VR; Bence, AK; Burke, TG; Mattingly, CA | 1 |
| Ohashi, Y; Yamaguchi, T | 1 |
| Humblet, Y | 1 |
| Agelidou, A; Ardavanis, A; Boukovinas, I; Georgoulias, V; Kouroussis, C; Palamidas, P; Polyzos, A; Stavrinidis, E; Syrigos, K; Toubis, M; Tselepatiotis, E; Veslemes, M; Vlachonikolis, I | 1 |
| Langer, CJ | 3 |
| Fukuda, M; Inoue, Y; Kasai, T; Kinoshita, A; Kohno, S; Kuba, M; Nagashima, S; Nakamura, Y; Oka, M; Soda, H; Soejima, Y; Takatani, H; Tsurutani, J | 1 |
| D'Haene, N; Darro, F; Gaussin, JF; Kiss, R; Mathieu, A; Penant, S; Remmelink, M; Salmon, I; Van Ginckel, R | 1 |
| Ishii, T; Matsuse, T; Teramoto, S | 1 |
| Detterbeck, FC; Fraser, R; Halle, JS; Hensing, TA; Limentani, SA; Mears, A; Moore, DT; Morris, DE; Rivera, MP; Rosenman, JG; Socinski, MA; Tynan, M | 1 |
| Adachi, M; Horichi, N; Ichikawa, I; Imai, T; Kashiwabara, Y; Kiuchi, Y; Kogo, M; Koichi, K; Murayama, J; Saito, Y | 1 |
| Biesma, B; Groen, HJ; Postmus, PE; Schramel, FM; Smit, EF; Stigt, JA; Wachters, FM | 1 |
| Economopoulos, T; Farmakis, D; Gaglia, A; Kostopoulou, V; Koumpou, M; Mylonakis, N; Nikolaou, M; Pectasides, D; Pectasides, M; Raptis, SA; Xiros, N | 1 |
| Govindan, R; McLeod, H; Read, W | 1 |
| Dumontet, C; Sève, P | 1 |
| Horai, T; Matsuda, M; Nakagawa, K; Nishio, M; Ohyanagi, F; Okumura, S; Sato, Y; Taguch, F | 1 |
| Chen, SY; Kussick, SJ; Roberson, RS; Vallieres, E; Wu, DY | 1 |
| Hamanaka, N; Ikehara, M; Noda, K; Oshita, F; Saito, H; Yamada, K | 1 |
| Green, MR; Gu, L; Herndon, JE; Miller, AA | 1 |
| Berdzik, J; Creaven, PJ; Hoffman, JL; Intengan, ME; Javle, MM; Khushalani, N; Litwin, AM; Pendyala, L; Ramnath, N; Rustum, YM; Slocum, HK; Smith, PF; Stewart, CC; Toth, K | 1 |
| Ueoka, H | 1 |
| Masuda, N; Yanase, N; Yokoba, M | 1 |
| Achiwa, H; Bessho, Y; Maeda, H; Muramatsu, H; Niimi, T; Oguri, T; Sato, S; Ueda, R | 2 |
| Agelidou, A; Androulakis, N; Boukovinas, I; Chandrinos, V; Georgoulias, V; Ignatiadis, M; Kentepozidis, N; Mylonaki, E; Vossos, A; Zachariadis, E; Ziotopoulos, P | 1 |
| Baka, S; Danson, S; Hoogendam, I; Linton, K; Lorigan, P; Mettinger, K; Ranson, M; Thatcher, N | 1 |
| Argiris, A; Avram, MJ; Kut, V; Luong, L | 1 |
| Eguchi, K; Kobayashi, K; Matsumoto, T; Morita, S; Ohashi, Y; Shibuya, M; Yamaji, Y | 1 |
| Agelidou, A; Agelidou, M; Androulakis, N; Athanasiadis, A; Georgoulias, V; Kalbakis, K; Mavroudis, D; Nikolakopoulos, J; Polyzos, A; Rapti, A; Samonis, G; Syrigos, K; Tselepatiotis, E | 1 |
| Kaneda, T; Narita, Y; Suzuki, A; Takahashi, N; Tsunematsu, K | 1 |
| Antoniou, D; Armenaki, O; Dimitroulis, J; Grigoratou, T; Katis, C; Marosis, C; Michalopoulou, P; Stathopoulos, GP; Stathopoulos, J; Tsavdaridis, D | 1 |
| Andersen, N; Brandt, D; Davies, MJ; Murren, JR; Nadkarni, R; Parisot, N; Pizzorno, G; Psyrri, D; Rose, M; Rosenfield, AT; Zelterman, D | 1 |
| Hojo, M; Izumi, S; Kamimura, M; Kobayashi, K; Kudo, K; Naka, G; Takeda, Y; Tsuduki, E | 1 |
| Han, JY; Kim, HT; Kim, HY; Lee, DH; Lee, HG; Lee, JJ; Lee, JS; Lee, SY; Park, CG | 1 |
| Lokich, J | 1 |
| Asaka-Amano, Y; Itoh, H; Kasahara, Y; Kuriyama, T; Kurosu, K; Takiguchi, Y; Tanabe, N; Tatsumi, K; Uno, T; Uruma, R | 1 |
| Han, JY; Ju, SY; Kim, HY; Lee, DH; Lee, JS; Lee, SY; Lim, HS; Park, CG; Park, YH | 1 |
| Ballas, MS; Dennis, PA | 1 |
| Adami, G; Belvedere, O; Ceschia, T; Fasola, G; Grossi, F; Meduri, S; Recchia, L; Rizzato, S; Rossetto, C; Sacco, C; Sibau, A; Spizzo, R; Tumolo, S; Vigevani, E | 1 |
| Fukuda, M; Kitazaki, T; Kohno, S; Nagashima, S; Nakamura, Y; Oka, M; Shiozawa, K; Soda, H; Takemura, M; Tsukamoto, K; Yabuuchi, H | 1 |
| Bartlett, DW; Cheng, J; Davis, ME; Heidel, JD; Hollister, B; Hwang, J; Schluep, T | 1 |
| Iwashige, A; Kagami, S; Tsukada, J; Uramoto, H | 1 |
| Kalofonos, HP; Karabelis, A; Kosmas, C; Koutras, A; Makatsoris, T; Mylonakis, N; Stathopoulos, GP; Syrigos, K; Tsakonas, G; Tsavaris, N | 1 |
| Innocenti, F; Ratain, MJ; Vokes, EE | 1 |
| Han, JY; Jang, IJ; Lee, DH; Lee, JE; Lee, JS; Lim, HS; Park, YH; Shin, ES; Yoo, YK | 1 |
| Cheng, Y; He, Q; He, X; Hu, Y; Lu, W; Luo, P; Yang, B | 1 |
| Kobayashi, K; Sutani, A | 1 |
| Fukumoto, H; Kiura, K; Koizumi, F; Nishio, K; Saijo, N; Shimoyama, T; Tanimoto, M | 1 |
| Fournel, P | 1 |
| Sandler, AB | 1 |
| Antoniou, D; Chaimala, D; Chondrou, E; Dariotaki, F; Karydis, I; Papageorgiou, C; Pavlakou, G; Stathopoulos, GP; Veslemes, M | 1 |
| Chun, JH; Han, JY; Kim, HT; Kim, HY; Lee, DH; Lee, HG; Lee, JJ; Lee, JS; Lee, SY | 1 |
| Abe, T; Arai, S; Hagiri, S; Katagiri, M; Kobayashi, H; Kubota, M; Masuda, N; Mitsufuji, H; Onoda, S; Ryuge, S; Wada, M; Yamamoto, M; Yanaihara, T; Yanase, N; Yokoba, M | 1 |
| Horai, T; Kasahara, K; Nishio, M; Ohyanagi, F; Shibata, K; Shirosaki, H; Taguchi, F; Takeda, Y | 1 |
| Katakami, N | 1 |
| Anantha, M; Bally, M; Ramsay, E; Zastre, J | 1 |
| Kudoh, S; Matsui, K; Nakagawa, K; Negoro, S; Saito, H; Semba, H; Takada, M | 1 |
| Hamaguchi, T; Kitagawa, M; Koizumi, F; Matsumoto, S; Matsumura, Y; Negishi, T; Onda, T | 1 |
| Altorki, NK; Bonomi, P; Fayyad, R; Hariharan, S; Hart, LL; Keresztes, RS; Lilenbaum, R; Morrison, ME; Socinski, MA | 1 |
| Ariyoshi, Y; Fukuoka, M; Kubota, K; Nakagawa, K; Negoro, S; Nishiwaki, Y; Ohashi, Y; Ohe, Y; Saijo, N; Tamura, T | 1 |
| Begum, S; Brock, M; Califano, JA; Liu, C; Sidransky, D; Westra, WH; Zhou, S | 1 |
| Carnahan, MA; Grinstaff, MW; Griset, AP; Kroll, DJ; Manikumar, G; Morgan, MT; Nakanishi, Y; Oberlies, NH; Wani, MC; Wathier, M | 1 |
| Hanada, M; Noguchi, T; Yamaoka, T | 1 |
| Miyagi, Y; Noda, K; Oshita, F; Saito, H; Sekiyama, A; Yamada, K | 1 |
| Adachi, M; Ando, K; Hirose, T; Hosaka, T; Ishida, H; Kusumoto, S; Nakashima, M; Ohmori, T; Shirai, T; Sugiyama, T | 1 |
| Ono, A; Yamamoto, N | 1 |
| Chu, DT; Han, FC; Liu, DQ; Xiu, QY; Zhang, XR; Zhu, YZ | 1 |
| Choong, NW; Hoffman, PC; Kozloff, M; Mauer, AM; Rudin, CM; Sciortino, DF; Szeto, L; Villano, JL; Vokes, EE; Wade, JL; Winegarden, JD | 1 |
| Mehta, M; Robins, HI; Traynor, AM | 1 |
| Atkins, JN; Bearden, JD; Case, D; Giguere, JK; Miller, AA | 1 |
| Cummings, K; Gao, F; Govindan, R; Hennenfent, KL; Marsh, S; McLeod, HL; Pillot, GA; Read, WL; Viswanathan, A | 1 |
| Bessho, A; Fujimoto, N; Fujiwara, K; Gemba, K; Hotta, K; Kiura, K; Kuyama, S; Segawa, Y; Shibayama, T; Shinkai, T; Tabata, M; Takata, I; Takigawa, N; Tanimoto, M; Tokuda, Y; Ueoka, H | 1 |
| Feigenberg, S; Huang, C; Langer, CJ; Litwin, S; Maiale, C; Millenson, M; Movsas, B; Nicoloau, N; Sherman, E; Somer, R; Treat, J | 1 |
| Hosomi, Y; Shibuya, M | 1 |
| Yoneda, S | 1 |
| Assaraf, YG; Bram, EE; Grimberg, M; Ifergan, I; Lemke, K; Skladanowski, A | 1 |
| Han, JY; Kim, HT; Lee, DH; Lee, JE; Lee, JS; Lee, SY; Lim, HS; Park, YH; Shin, ES; Yoo, YK | 1 |
| Oshita, F; Saito, H; Yamada, K | 1 |
| Fukuda, M; Kinoshita, A; Kohno, S; Nagashima, S; Nakamura, Y; Oka, M; Soda, H; Takatani, H; Tsukamoto, K | 1 |
| Fukuda, M; Kinoshita, A; Kohno, S; Nagashima, S; Nakamura, Y; Nakano, H; Oka, M; Soda, H; Soejima, Y; Takatani, H | 1 |
| Chowbay, B; Goh, BC; Jada, SR; Lee, SC; Lim, R; Shu, X; Wong, CI; Zhou, Q | 1 |
| Asaka-Amano, Y; Kawashima, T; Kuriyama, T; Kurosu, K; Moriya, T; Nagao, K; Tada, Y; Takiguchi, Y | 1 |
| Boku, N; Yamazaki, K; Yoshino, T | 1 |
| Fukuda, M; Kinoshita, A; Kohno, S; Nagashima, S; Nakamura, Y; Nakano, H; Oka, M; Soda, H; Soejima, Y; Takatani, H; Tomonaga, N | 1 |
| Noda, K; Oshita, F; Saito, H; Yamada, K | 2 |
| Han, JY; Kim, HT; Lee, JE; Lee, JS; Lim, HS; Park, YH; Shin, ES; Yoo, YK | 1 |
| Baggstrom, MQ; Fried, DB; Hensing, TA; Poole, C; Socinski, MA; Stinchcombe, TE | 1 |
| Chak, K; Chan, AT; Chan, G; Ho, S; Ho, WM; Lam, KC; Lee, Y; Mok, TS; Wong, H; Yeo, W; Yim, AP | 1 |
| Burris, HA; Grapski, R; Greco, FA; Hainsworth, JD; Mallidi, PV; Meng, C; Schreeder, M; Simons, L; Spigel, DR; Yardley, DA | 1 |
| Bachelot, T; Biron, P; Blay, JY; Brantus, JF; Confavreux, C; Ghesquière, H; Guastalla, JP; Ray-Coquard, I; Rustam, F; Saba, C; Sebban, C | 1 |
| Seto, T | 1 |
| Aoe, M; Date, H; Fujii, T; Fujiwara, Y; Hotta, K; Ichimura, K; Kiura, K; Kobayashi, N; Soh, J; Suehisa, H; Toyooka, S; Yoshino, T | 1 |
| Bandyopadhyay, K; Banères, JL; Gjerset, RA; Haghighi, A; Lee, C; Parello, J | 1 |
| Choong, NW; Ferguson, MK; Haraf, DJ; Hoffman, PC; Kasza, K; Krauss, SA; Mauer, AM; Rudin, CM; Szeto, L; Tothy, PK; Vokes, EE | 1 |
| Charoentum, C; Chewasakulyong, B; Euathrongchit, J; Munprakan, S; Sorraritchingchai, S; Thongprasert, S | 1 |
| Aragane, N; Fukuno, Y; Hayashi, S; Kawaura, F; Komiya, K; Tanaka, A | 1 |
| Han, JY; Lee, JS; Lee, SY; Lim, HS; Park, YH | 1 |
| Halle, JS; Hayes, DN; Lee, CB; Moore, DT; Morris, DE; Rivera, MP; Rosenman, JG; Socinski, MA; Stinchcombe, TE | 1 |
| Aitini, E; Amoroso, V; Ardizzoia, A; Bajetta, E; Bandera, M; Bidoli, P; Cortinovis, D; Cullurà, D; Fusi, A; Lorusso, V; Radula, D; Zilembo, N | 1 |
| Han, JY; Kim, HT; Kim, HY; Lee, DH; Lee, JS; Lee, SY; Song, JE | 1 |
| Fukuoka, M; Hirashima, T; Kudoh, S; Kusunoki, Y; Masuda, N; Matsui, K; Nakagawa, K; Nitta, T; Tamanoi, M; Yana, T | 1 |
| Fukuoka, M; Hirashima, T; Kudoh, S; Kusunoki, Y; Masuda, N; Matsui, K; Nakagawa, K; Takada, M; Tsukada, H; Yana, T | 1 |
| Fields, SZ; Hargis, JB; Lilenbaum, RC; Miller, AA; Rosner, GL; Schilsky, RL | 1 |
| Ardizzoni, A | 1 |
| Comis, RL; Friedland, DM | 1 |
| Taguchi, T | 1 |
| Cheson, B; Christian, M; Feigal, EG; Friedman, MA; Grever, M | 1 |
| Grant, SC; Kris, MG | 1 |
| Klastersky, J | 1 |
| Funayama, Y; Isogai, Y; Kanzawa, F; Kuraishi, Y; Lee, YS; Nishio, K; Ogasawara, H; Ohira, T; Saijo, N | 1 |
| Fukuoka, M; Hirashima, T; Kudoh, S; Kusunoki, Y; Masuda, N; Matsui, K; Nakagawa, K; Negoro, S; Takifuji, N; Yoshikawa, A | 1 |
| Grant, SC; Kris, MG; Miller, VA; Pisters, KM; Rigas, JR | 1 |
| Fukuoka, M; Yoshikawa, A | 1 |
| Fukuoka, M; Masuda, N | 1 |
| Eguchi, K; Kanzawa, F; Karato, A; Kubota, N; Nishio, K; Ohe, Y; Saijo, N; Sasaki, Y; Shinkai, T; Tamura, T | 1 |
| Elias, A; Frei, E; Kalish, L; Lynch, TJ; Posner, M; Shulman, LN; Skarin, A; Strauss, G | 1 |
| Arioka, H; Eguchi, K; Karato, A; Kunikane, H; Nishio, M; Ohe, Y; Oshita, F; Sasaki, Y; Shinkai, T; Tamura, T | 1 |
| Itoh, K; Kudoh, S; Kusunoki, Y; Masuda, N; Matsui, K; Morino, H; Nakagawa, K; Negoro, S; Takada, M; Takifuji, N | 1 |
| Edelman, MJ; Gandara, DR | 1 |
| Fossella, FV; Glisson, BS; Hong, WK; Huber, MH; Kane, J; Kemp, BL; Kurie, JM; Lee, JJ; Lee, JS; Lippman, SM; Murphy, WK; Perez-Soler, R; Raber, MN; Robinson, RA; Shin, DM | 1 |
| Dunlop, DJ; Steward, WP | 1 |
| Emami, B; Graham, MV; Harms, W; Matthews, J; Purdy, JA | 1 |
| Fujita, A; Sekine, K; Tagaki, S; Takabatake, H | 4 |
| Cooper, JD; Dresler, CM; Emami, B; Graham, MV; Jahanzeb, M; Mortimer, JE | 1 |
| Arbuck, SG; Dimery, I; Muggia, FM | 1 |
| Abe, S; Fujita, A; Hayashi, I; Kawakami, Y; Kurita, Y; Matsuda, T; Nakabayashi, T; Nishiwaki, Y; Noda, K; Oshita, F; Saijo, N; Suzuki, S; Takahashi, S; Tamura, T; Tobise, K; Tsuchiya, S | 1 |
| Hasegawa, Y; Mogi, H; Nomura, F; Saka, H; Shimokata, K; Watanabe, A | 1 |
| Mori, K; Ohnishi, T; Tominaga, K; Yokoyama, K | 1 |
| Bai, F; Hara, N; Kawasaki, M; Mizuno, K; Nakanishi, Y; Pei, XH; Takayama, K; Tsuruta, N | 1 |
| Heuser, A; Sauer, R | 1 |
| Hirose, T; Machida, S; Mori, K; Tominaga, K; Yokoyama, K | 1 |
| Fukuoka, M; Furuse, K; Kudoh, S; Kurita, Y; Niitani, H; Ohnoshi, T; Saijoh, N | 1 |
| Saijo, N; Shinkai, T | 1 |
| Belani, CP; Ramanathan, RK | 1 |
| Furuse, K | 1 |
| Masuda, N | 2 |
| Ando, M; Eguchi, K; Hojo, N; Kakinuma, R; Kasai, T; Kodama, T; Kubota, K; Kurata, T; Matsumoto, T; Nishiwaki, Y; Ohe, Y; Ohmatsu, H; Saijo, N; Sekine, I; Shinkai, T; Tamura, T; Yamamoto, N | 1 |
| Adachi, J; Arioka, H; Fukumoto, H; Fukuoka, K; Ishida, T; Kurokawa, H; Narita, N; Nishio, K; Nomoto, T; Saijo, N; Tomonari, A; Yokota, J; Yokote, H | 1 |
| Saijo, N | 2 |
| Natale, RB | 1 |
| Fujimoto, M; Fujiwara, M; Hasegawa, S; Ishikawa, H; Kamma, H; Ohtsuka, M; Satoh, H; Yamashita, YT; Yazawa, T | 1 |
| Bunn, PA; Kelly, K | 1 |
| Kunikane, H; Kunitoh, H; Nagatomo, A; Okamoto, H; Watanabe, K | 1 |
| Hibino, S; Hino, M; Kabe, J; Kamimura, M; Kobayashi, K; Kudo, K; Kudoh, S; Shibuya, M; Shinbara, A; Takeda, Y | 1 |
| Boven, E; Dingemans, AM; Giaccone, G; Jansen, WJ; Kedde, MA; Pinedo, HM; van Ark-Otte, J; van der Vijgh, WJ | 1 |
| Fujita, A; Fukuoka, M; Katakami, N; Kurita, Y; Masuda, N; Nagao, K; Nakagawa, K; Negoro, S; Niitani, H; Nishikawa, H; Tsuchiya, S | 1 |
| Kurita, Y; Matsuda, T; Noda, K; Saijo, N; Shimokata, K; Tamura, T; Yokoyama, A | 1 |
| Belani, CP | 1 |
| Crawford, J; Garst, J; Persons, DA; Vollmer, R | 1 |
| Crawford, J; Devore, R; Dimery, I; Eckardt, J; Eckhardt, SG; Johnson, D | 1 |
| Rosen, LS | 1 |
| Abe, S; Hayashi, I; Kawakami, Y; Kurita, Y; Matsuda, T; Nakabayashi, T; Nishiwaki, Y; Saijo, N; Suzuki, S; Takahashi, T; Tamura, T; Yamamoto, N | 1 |
| Ansari, RH; Fishkin, PA; Golomb, HM; Hoffman, PC; Klepsch, A; Krauss, S; Lad, TE; Masters, GA; Ratain, MJ; Sciortino, DF; Vokes, EE | 1 |
| Asano, T; Kawaji, K; Kobayashi, M; Mukai, J; Namikawa, O; Sano, T; Yamamoto, A | 1 |
| Armand, JP; Couteau, C | 1 |
| Chikamori, K; Gemba, K; Harada, M; Hiraki, S; Kiura, K; Segawa, Y; Shibayama, T; Tabata, M; Ueoka, H; Yonei, T | 1 |
| Baguley, BC; Bridewell, DJ; Finlay, GJ | 1 |
| Fukuoka, M; Kudoh, S; Masuda, N; Nakajima, T; Negoro, S; Okishio, K; Tada, T; Takada, M; Takeda, K; Tanaka, M | 1 |
| Shepherd, FA | 1 |
| Kano, Y; Machida, S; Mori, K; Tominaga, K; Yoshida, M; Yoshida, T | 1 |
| Lad, TE; Minami, H; Nicholas, MK; Ratain, MJ; Vokes, EE | 1 |
| Fujita, A; Igami, Y; Sekine, K; Tagaki, S; Takabatake, H; Yamamoto, R | 1 |
| Hara, N; Inoue, K; Kawasaki, M; Minami, T; Nakanishi, Y; Osaki, S; Takaki, Y; Takano, K; Takayama, K; Wataya, H | 1 |
| Ardizzoni, A; de Cupis, A; Favoni, RE; Grossi, F; Loprevite, M; Merlo, F; Pirani, P | 1 |
| Crawford, J; DeVore, RF; Dimery, IW; Eckardt, J; Eckhardt, SG; Elfring, GL; Garst, J; Hanover, CK; Johnson, DH; Miller, LL; Schaaf, LJ | 1 |
| Bengtson, EM; Rigas, JR | 1 |
| Adjei, AA; Argiris, A; Murren, JR | 1 |
| Bahadori, HR; Eckardt, JR; Green, MR; Leong, SS; Perkel, JA; Putman, T; Rocha Lima, CM; Safa, AR; Sherman, CA | 1 |
| Sandler, A; van Oosterom, AT | 1 |
| Arioka, H; Fukumoto, H; Fukuoka, K; Ishida, T; Iwamoto, Y; Kurokawa, H; Narita, N; Nishio, K; Saijo, N; Suzuki, T; Tomonari, A; Usuda, J | 1 |
| Fujita, A; Fukuoka, M; Katakami, N; Kurita, Y; Nagao, K; Nakano, M; Negoro, S; Niitani, H; Saito, R | 1 |
| Dombernowsky, P; Drings, P; Hanauske, AR; Morant, R; Nielsen, D; Roelvink, M; Sessa, C; Wanders, J; Wissel, P | 1 |
| Fukuoka, M | 2 |
| Arimoto, J; Bessho, T; Furukawa, T; Hirai, I; Maebeya, S; Matsuyama, K; Naito, Y; Oura, S; Sakurai, T; Suzuma, T; Tanino, H; Yano, T; Yoshimasu, T | 1 |
| Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Kremos, S; Mavroudis, D; Souglakos, J | 1 |
| Fukuoka, M; Kudoh, S; Masuda, N; Nakagawa, K; Negoro, S; Niitani, H; Saka, H; Sugiura, T; Takada, M | 1 |
| Buccheri, G; Ferrigno, D | 1 |
| Sandler, A | 1 |
| Israel, VP; Miller, L; Natale, RB; Sandler, A; Socinski, M | 1 |
| Chakravarthy, A; Choy, H; Devore, RF; Hande, KR; Jagasia, M; Johnson, DH; Roberts, JR; Yunus, F | 1 |
| Gamucci, T; Hanauske, A; Heinrich, B; Kaye, S; Paridaens, R; Pavlidis, N; Roelvink, M; Schellens, JH; Sessa, C; Verweij, J; Wanders, J | 1 |
| Boven, E; Hausheer, FH; Pinedo, HM; Schlüper, HM; Van Hattum, AH | 1 |
| Bukowski, RM; Ganapathi, MK; Ganapathi, R; Grabowski, DR; Tabata, M; Tabata, R | 1 |
| Agelaki, S; Georgoulias, V; Kakolyris, S; Kourousis, CH; Malliotakis, P; Mavroudis, D; Sarra, E; Souglakos, J | 1 |
| Charnsangavej, C; Chow, D; Hung, MC; Li, C; Tansey, W; Wallace, S; Wu, QP; Zou, Y | 1 |
| Elfring, GL; Hanover, CK; Israel, VK; Locker, PK; Miller, LL; Natale, RB; Pirotta, N; Sandler, AB; Socinski, MA | 1 |
| Bhatt, R; De Vries, P; Klein, P; Lewis, RA; Li, C; Milas, L; Singer, JW; Tulinsky, J; Wallace, S | 1 |
| Ganapathi, R; Tabata, M | 1 |
| Fukumoto, H; Kanzawa, F; Koh, Y; Koizumi, F; Nakamura, T; Nishio, K; Saijo, N; Tatsumi, Y; Yoshioka, T | 1 |
| Carbone, DP; Cohen, AG; Devore, RF; Jagasia, MH; Johnson, DH; Langer, CJ; Rodgers, JS; Schlabach, LL; Shyr, Y; Yunus, F | 1 |
| Carenini, N; Dallavalle, S; De Cesare, M; Ferrari, A; Merlini, L; Penco, S; Perego, P; Pratesi, G; Zunino, F | 1 |
| Blum, K; Gallipoli , M; McKeon, A; Murren, JR; Rich, R | 1 |
| Choy, H; MacRae, R | 2 |
| Johnson, DH | 1 |
| Bonomi, P; Shirazi, W | 1 |
| Belani, CP; Calvo, AR | 1 |
| Fukuda, M; Hayashi, N; Ichiki, M; Kinoshita, A; Kohno, S; Kuba, M; Nagashima, S; Nakamura, Y; Narasaki, F; Oka, M; Rikimaru, T; Soda, H; Takatani, H | 1 |
| Eguchi, K; Harada, M; Harita, S; Hiraki, S; Kamei, H; Kiura, K; Okimoto, N; Segawa, Y; Shibayama, T; Tabata, M; Takata, I; Takigawa, N; Tanimoto, M; Ueoka, H; Watanabe, Y | 1 |
| Rigas, JR | 1 |
| Murren, JR | 1 |
| Brunson, CY; Green, MR; Kneuper-Hall, R; Lal, A; Rocha Lima, CM; Urbanic, JJ | 1 |
| Inoue, A; Saijo, N | 1 |
| Arrieta, R; Golomb, HM; Gordon, GS; Hoffman, PC; Krauss, S; Mauer, AM; Rudin, CM; Vokes, EE; Watson, S | 1 |
| Fukuoka, M; Negoro, S; Nitta, T; Takeda, K; Takifuji, N; Terakawa, K; Yoshimura, N | 1 |
| Bucci, F; Capocasa, F; Carenini, N; Carminati, P; De Cesare, M; Merlini, L; Pace, S; Penco, S; Perego, P; Pisano, C; Pratesi, G; Tinelli, S; Vesci, L; Zunino, F | 1 |
| Boccieri, MG; Bruschi, G; Lo Re, G; Saracchini, S; Toffoli, G; Tumolo, S | 1 |
| Agelaki, S; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Souglakos, J; Vamvakas, L; Vardakis, N | 1 |
| Caffo, O | 1 |
| Carney, DN | 1 |
| Baptiste, N; Chen, X; Friedlander, P; Prives, C | 1 |
| Ando, M; Ando, Y; Hasegawa, Y; Ikeda, T; Minami, H; Saka, H; Sakai, S; Sato, M; Sekido, Y; Shimokata, K; Watanabe, A; Yamamoto, M | 1 |
| Fukuoka, M; Hirashima, T; Komiya, T; Nakagawa, K; Nitta, T; Syunichi, N; Tada, H; Tohda, A; Tsurutani, J; Uejima, H | 1 |
| Andou, A; Aoe, M; Date, H; Kiura, K; Shibayama, T; Shimizu, N; Tabata, M; Ueoka, H | 1 |
| Kato, Y; Saijo, N | 1 |
| Mavroudis, D | 1 |
| Kato, H; Tsuboi, M | 1 |
| Athanassiou, A; Bountouroglou, N; Glotsos, J; Karvounis, N; Kouloubinis, A; Pectasides, D; Visvikis, A; Ziras, N | 1 |
| Fujita, A; Hoshino, H; Ohkubo, T; Sekine, K; Tagaki, S; Takabatake, H | 1 |
| Yokoyama, A | 1 |
| Ariyoshi, Y; Fukuoka, M; Hasegawa, K; Kuriyama, T; Masuda, N; Motomiya, M; Negoro, S; Niitani, H; Nishiwaki, Y; Suzuki, A | 1 |
| Ettinger, DS; Forastiere, AA; Grochow, LB; Hendricks, CB; Hurowitz, LA; Kaufmann, SH; Lubejko, BG; McGuire, WP; Rowinsky, EK; Sartorius, SE | 1 |
| Beck, H; Capranico, G; Gazdar, AF; Giaccone, G; Zunino, F | 1 |
| Eguchi, K; Karato, A; Kojima, A; Kunikane, H; Ohe, Y; Ohmatsu, H; Okamoto, H; Sasaki, Y; Shinkai, T; Tamura, T | 1 |
| Fukuoka, M; Kishimoto, S; Kudoh, S; Kusunoki, Y; Masuda, N; Matsui, K; Nakagawa, K; Negoro, S; Takada, M; Takifuji, N | 1 |
| Ariyoshi, Y; Sugiura, T | 1 |
| Mukai, K; Nagane, M; Nomura, K; Oyama, H; Shibui, S | 1 |
| Pautier, P | 1 |
| Fukuoka, M; Kudoh, S; Kusunoki, Y; Masuda, N; Matsui, K; Negoro, S; Niitani, H; Taguchi, T; Takada, M; Takifuji, N | 1 |
| Fukuoka, M; Furue, H; Hara, N; Hara, Y; Hasegawa, K; Negoro, S; Niitani, H; Taguchi, T | 1 |
| Bungo, M; Fujiwara, Y; Kanzawa, F; Kasahara, K; Liu, LF; Minato, K; Nakagawa, K; Saijo, N; Sugimoto, Y | 1 |
86 review(s) available for camptothecin and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Trastuzumab Deruxtecan-Induced Interstitial Lung Disease/Pneumonitis in ERBB2-Positive Advanced Solid Malignancies: A Systematic Review.
Topics: Adult; Camptothecin; Carcinoma, Non-Small-Cell Lung; Humans; Immunoconjugates; Lung Diseases, Interstitial; Lung Neoplasms; Pneumonia; Receptor, ErbB-2; Trastuzumab | 2022 |
TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC).
Topics: Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Humans; Immunoconjugates; Irinotecan; Lung Neoplasms | 2023 |
Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; Female; Humans; Immunoconjugates; Lung Neoplasms; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2019 |
Comparison of first-line chemotherapy based on irinotecan or other drugs to treat non-small cell lung cancer in stage IIIB/IV: a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Treatment Outcome | 2015 |
Comparison of nedaplatin and irinotecan for patients with squamous and nonsquamous cell carcinoma of the lung: meta-analysis of four trials.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Pilot Projects; Risk Factors; Survival Rate; Treatment Outcome | 2011 |
A preclinical and clinical review of aflibercept for the management of cancer.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Colorectal Neoplasms; Disease-Free Survival; Drug Screening Assays, Antitumor; Fluorouracil; Humans; Leucovorin; Lung Neoplasms; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Vascular Endothelial Growth Factor A | 2012 |
Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Docetaxel; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Perspectives and opportunities: Docetaxel in the current and future treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2002 |
Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Palliative Care; Randomized Controlled Trials as Topic; Vinblastine; Vinorelbine | 2002 |
[Randomized controlled trials in Japan--lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Irinotecan; Lung Neoplasms; Meta-Analysis as Topic; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Taxoids | 2002 |
Irinotecan in combination with radiation therapy for small-cell and non-small-cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Humans; Irinotecan; Lung Neoplasms; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic | 2002 |
Current role of irinotecan in the treatment of non-small-cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Irinotecan; Lung Neoplasms; Organoplatinum Compounds; Taxoids | 2002 |
Non-platinum gemcitabine combinations in non-small cell lung cancer.
Topics: Aged; Aging; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Survival; Taxoids; Treatment Outcome | 2002 |
Challenging the platinum combinations in the chemotherapy of NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neutropenia; Paclitaxel; Taxoids | 2002 |
Molecular markers and targeted therapy with novel agents: prospects in the treatment of non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Combined Modality Therapy; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Endonucleases; ErbB Receptors; Humans; Irinotecan; Lung Neoplasms; Predictive Value of Tests; Protein Biosynthesis; Proteins; Radiotherapy, Adjuvant; Ribonucleotide Reductases | 2002 |
The camptothecins.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bone Marrow; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Diarrhea; Female; Gastrointestinal Neoplasms; Humans; Lung Neoplasms; Ovarian Neoplasms; Structure-Activity Relationship; Topoisomerase I Inhibitors | 2003 |
Advanced NSCLC: new cytostatic agents.
Topics: Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Epothilones; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Thymidylate Synthase | 2003 |
[Current status of camptothecin derivatives as natural antitumor agents].
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Structure-Activity Relationship; Topotecan; Tumor Cells, Cultured | 2003 |
Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids; Treatment Outcome | 2004 |
Chemoresistance in non-small cell lung cancer.
Topics: Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Tubulin; Vinblastine; Vinorelbine | 2005 |
[Chemotherapy for advanced non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2005 |
[New anti-cancer agents--from cytotoxic systemic chemotherapy to target-based agents].
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Boronic Acids; Bortezomib; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Erlotinib Hydrochloride; Furans; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Oxonic Acid; Pemetrexed; Pyrazines; Pyridines; Quinazolines; Tegafur; Vinblastine; Vinorelbine | 2005 |
[Chemotherapy for lung cancer patients].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Erlotinib Hydrochloride; Etoposide; Evidence-Based Medicine; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Taxoids | 2006 |
[Lung carcinoma].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Quality of Life; Vinblastine; Vinorelbine | 2006 |
Nondermatologic adverse events associated with anti-EGFR therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Irinotecan; Lung Diseases, Interstitial; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2006 |
[Lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Administration Schedule; Etoposide; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Pemetrexed; Taxoids | 2007 |
[Non-cisplatin based chemotherapy in advanced non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2007 |
[Bevacizumab (Avastin)].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Colonic Neoplasms; Drug Administration Schedule; Drug Approval; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Lung Neoplasms; Male; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Vascular Endothelial Growth Factor A | 2007 |
Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Immunosuppressive Agents; Irinotecan; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2007 |
[Are antiangiogenic antibodies universal for solid tumor?].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Fluorouracil; Humans; Hypertension; Kidney Neoplasms; Leucovorin; Lung Neoplasms; Neoplasms; Neovascularization, Pathologic; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2007 |
[Chemotherapy in lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Survival Rate | 2007 |
Camptothecin analogues in the treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Drug Evaluation, Preclinical; Humans; Lung Neoplasms; Topotecan | 1995 |
New chemotherapy agents in the treatment of advanced non-small cell lung cancer: an update including data from the Seventh World Conference on Lung Cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Design; Growth Substances; Humans; Interferons; Interleukins; Lung Neoplasms; Paclitaxel; Tumor Cells, Cultured | 1995 |
Clinical studies of CPT-11 in Japan.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Remission Induction; Uterine Neoplasms | 1995 |
New chemotherapeutic agents in non-small-cell lung cancer.
Topics: Aminopterin; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Design; Humans; Interferons; Irinotecan; Lung Neoplasms; Paclitaxel; Topotecan; Vinblastine; Vinorelbine | 1993 |
New antineoplastic agents in lung cancer 1988-1993.
Topics: Aminopterin; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Humans; Irinotecan; Lung Neoplasms; Nitrosourea Compounds; Organophosphorus Compounds; Paclitaxel; Teniposide; Vinblastine; Vinorelbine | 1995 |
New drug for therapy of non-small cell lung cancer.
Topics: Aminopterin; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1994 |
New chemotherapeutic agents for non-small cell lung cancer.
Topics: Aminopterin; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Quinoxalines; Sulfanilamides; Taxoids; Topotecan; Vinblastine; Vinorelbine | 1995 |
[Therapeutic strategy for advanced non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Vinblastine; Vinorelbine | 1995 |
7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin: mechanism of resistance and clinical trials.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Survival; CHO Cells; Clinical Trials, Phase I as Topic; Cricetinae; DNA Topoisomerases, Type I; Drug Resistance; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Molecular Sequence Data; Neoplasms; Ovarian Neoplasms; Point Mutation; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1994 |
New directions for chemotherapy in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Topotecan; Vinblastine; Vinorelbine | 1993 |
Promising new agents in the treatment of non-small cell lung cancer.
Topics: Aminopterin; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1996 |
New drugs in the treatment of non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Paclitaxel; Vinblastine; Vinorelbine | 1995 |
Camptothecin and its analogs. An overview of their potential in cancer therapeutics.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Female; Hematologic Neoplasms; Humans; Lung Neoplasms; Lymphoma, Non-Hodgkin; Ovarian Neoplasms; Uterine Neoplasms | 1996 |
[Topoisomerase I inhibitor with potential radiosensitizing effect].
Topics: Antineoplastic Agents; Brain Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Child; Clinical Trials as Topic; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms; Ovarian Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage; Topoisomerase I Inhibitors; Topotecan | 1997 |
[Chemotherapy for non-small cell lung cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Humans; Irinotecan; Lung Neoplasms; Platinum Compounds; Randomized Controlled Trials as Topic | 1996 |
Chemotherapy for advanced non-small cell lung cancer: past, present, and future.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1997 |
[Lung cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan; Vinblastine; Vinorelbine | 1997 |
[Combination chemotherapy in the treatment of inoperable non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Meta-Analysis as Topic; Mitomycin; Paclitaxel; Survival Rate; Vinblastine; Vindesine; Vinorelbine | 1997 |
New chemotherapeutic agents for the treatment of non-small cell lung cancer: the Japanese experience.
Topics: Alkaloids; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbazoles; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Glucosides; Humans; Irinotecan; Japan; Lung Neoplasms; Mitomycin; Mitomycins; Neoplasms, Experimental; Paclitaxel; Purine Nucleosides; Staurosporine; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 1998 |
Experience with new chemotherapeutic agents in non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Treatment Outcome | 1998 |
New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Taxoids; Topotecan; Vinblastine; Vinorelbine | 1998 |
Single agents in the second-line treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Treatment Failure; Vinblastine; Vinorelbine | 1998 |
Irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Drug Therapy, Combination; Humans; Irinotecan; Lung Neoplasms | 1998 |
Irinotecan in lymphoma, leukemia, and breast, pancreatic, ovarian, and small-cell lung cancers.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Irinotecan; Leukemia; Lung Neoplasms; Lymphoma; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms | 1998 |
[Irinotecan-containing combinations in solid tumors, except colonic carcinomas].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diarrhea; Docetaxel; Enzyme Inhibitors; Etoposide; Female; Genital Neoplasms, Female; Humans; Irinotecan; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Neoplasm Proteins; Neoplasms; Neutropenia; Paclitaxel; Stomach Neoplasms; Taxoids; Topoisomerase I Inhibitors; Treatment Outcome | 1998 |
Chemotherapy for non-small cell lung cancer: have we reached a new plateau?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Palliative Care; Randomized Controlled Trials as Topic; Tirapazamine; Triazines; Vinblastine; Vinorelbine | 1999 |
Docetaxel and irinotecan, alone and in combination, in the treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids | 1999 |
Single-agent gemcitabine and gemcitabine/irinotecan combination (irimogem) in non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Lung Neoplasms | 1999 |
Irinotecan in cancers of the lung and cervix.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Female; Humans; Irinotecan; Lung Neoplasms; Uterine Cervical Neoplasms | 1999 |
[Current perspectives of new agents in lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2000 |
Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drugs, Investigational; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Randomized Controlled Trials as Topic; Salvage Therapy; Taxoids; Vinblastine; Vinorelbine | 2000 |
Chemotherapy in metastatic non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Mitomycin; Paclitaxel; Taxoids; Tirapazamine; Triazines; Vinblastine; Vinorelbine | 2000 |
Weekly irinotecan and concurrent radiation therapy for stage III unresectable NSCLC.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Drug Evaluation, Preclinical; Humans; Irinotecan; Lung Neoplasms; Radiation-Sensitizing Agents | 2000 |
The role of new agents in advanced non-small-cell lung carcinoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Immunologic Factors; Irinotecan; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Neoplasm Staging; Prognosis; Quality of Life; Survival Analysis; Taxoids; Tomography, X-Ray Computed; Vinblastine; Vinorelbine | 2000 |
Preclinical and clinical trials of topoisomerase inhibitors.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Irinotecan; Lung Neoplasms; Topoisomerase I Inhibitors | 2000 |
Establishment of the standard regimen for non-small-cell lung cancer in Japan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Drug Administration Schedule; Female; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Vindesine | 2001 |
Rationale and dose-finding studies of the combination of irinotecan and a taxane on a weekly schedule.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Prognosis; Survival Rate; Taxoids | 2001 |
Irinotecan in combined-modality therapy for locally advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Humans; Irinotecan; Lung Neoplasms; Survival Rate | 2001 |
Irinotecan: summary and future directions.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Combined Modality Therapy; Forecasting; Humans; Irinotecan; Lung Neoplasms; Survival Analysis; United States | 2001 |
Current status of irinotecan in lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Humans; Irinotecan; Lung Neoplasms; Survival Rate | 2001 |
Chemoradiation in locally advanced non-small cell lung cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Forecasting; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Lung cancer: therapeutic options for stage IV and recurrent NSCLC.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Taxoids; Teniposide; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Non-platinum based combination chemotherapy: phase I and II trials of docetaxel plus gemcitabine, vinorelbine, or irinotecan.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2001 |
The emerging world role of irinotecan in lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Drug Synergism; Humans; Irinotecan; Japan; Lung Neoplasms; Paclitaxel; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome; United States | 2001 |
Irinotecan and radiation in combined-modality therapy for solid tumors.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Enzyme Inhibitors; Female; Gastrointestinal Neoplasms; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasms; Radiotherapy, Adjuvant; Topoisomerase I Inhibitors; Uterine Cervical Neoplasms | 2001 |
Rationale for non-platinum chemotherapy in advanced NSCLC.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2001 |
Beyond pancreatic cancer: irinotecan and gemcitabine in solid tumors and hematologic malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Gemcitabine; Hematologic Neoplasms; Humans; Irinotecan; Lung Neoplasms; Lymphoma, Non-Hodgkin; Pancreatic Neoplasms | 2001 |
Recent advances in the chemotherapy of non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Randomized Controlled Trials as Topic; Survival Rate; Tirapazamine; Triazines; Vinblastine; Vinorelbine | 2001 |
Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Doxorubicin; Enzyme Inhibitors; Etoposide; Gemcitabine; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Topotecan; Vinblastine; Vinorelbine | 2001 |
Radiosensitization with chemotherapeutic agents.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Platinum Compounds; Radiation-Sensitizing Agents; Taxoids; Vinblastine; Vinorelbine | 2001 |
[Developed new agents for lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Topotecan; Vinblastine; Vinorelbine | 2002 |
[New therapeutic approaches in non-small-cell lung carcinoma (NSCLC), stages IV].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Taxoids; Time Factors; Vinblastine; Vinorelbine | 2001 |
[Current status of the chemotherapy for lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Docetaxel; Drug Administration Schedule; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Survival Rate; Taxoids | 2002 |
[Irinotecan].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Etoposide; Humans; Irinotecan; Lung Neoplasms | 2002 |
[DNA topoisomerase inhibitor].
Topics: Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Mice; Phenazines; Topoisomerase I Inhibitors; Topotecan | 1992 |
172 trial(s) available for camptothecin and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Trastuzumab Deruxtecan in
Topics: Adult; Aged; Aged, 80 and over; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Follow-Up Studies; Humans; Immunoconjugates; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Pneumonia; Progression-Free Survival; Receptor, ErbB-2; Trastuzumab | 2022 |
Trastuzumab Deruxtecan in Patients With
Topics: Camptothecin; Carcinoma, Non-Small-Cell Lung; Humans; Immunoconjugates; Lung Neoplasms; Receptor, ErbB-2; Trastuzumab | 2023 |
Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Adhesion Molecules; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Immunoconjugates; Lung Neoplasms; Male; Middle Aged | 2017 |
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Docetaxel; Doxorubicin; Drug Eruptions; Fatigue; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasms; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Sarcoma; Small Cell Lung Carcinoma; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Vomiting | 2017 |
Phase II study of irinotecan as a third- or fourth-line treatment for advanced non-small cell lung cancer: NJLCG0703.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Administration Schedule; Endpoint Determination; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Salvage Therapy; Survival Rate; Treatment Outcome | 2013 |
Phase II study of weekly carboplatin and irinotecan as first-line chemotherapy for patients with advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging | 2013 |
Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Small Cell Lung Carcinoma; Survival Rate; Young Adult | 2013 |
Prospective study of paclitaxel and irinotecan for elderly patients with unresectable non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Prospective Studies; Survival Rate | 2013 |
A Phase II study of S-1 and irinotecan combination therapy in previously treated patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Drug Combinations; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Survival Analysis; Tegafur; Young Adult | 2015 |
Incorporating Erlotinib or Irinotecan Plus Cisplatin into Chemoradiotherapy for Stage III Non-small Cell Lung Cancer According to EGFR Mutation Status.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Irinotecan; Lung Neoplasms; Male; Mutation; Neoplasm Metastasis; Neoplasm Staging; Survival Analysis; Treatment Failure; Treatment Outcome | 2017 |
Population-based phase I trial of irinotecan and epirubicin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Administration Schedule; Drug Synergism; Epirubicin; Female; Gastrointestinal Neoplasms; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neutropenia; Topoisomerase I Inhibitors | 2008 |
Scheduled administration of low dose irinotecan before gemcitabine in the second line therapy of non-small cell lung cancer: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Survival Rate | 2008 |
Phase I/II pharmacokinetic and pharmacogenomic study of UGT1A1 polymorphism in elderly patients with advanced non-small cell lung cancer treated with irinotecan.
Topics: Aged; Aged, 80 and over; Camptothecin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Male; Neutropenia; Polymorphism, Genetic; Treatment Outcome | 2009 |
Phase II study of combination therapy with S-1 and irinotecan for advanced non-small cell lung cancer: west Japan thoracic oncology group 3505.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Combinations; Female; Humans; Irinotecan; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Tegafur; Treatment Outcome | 2008 |
Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Genetic; Survival Analysis | 2009 |
Phase I study of daily S-1 combined with weekly irinotecan in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Combinations; Feasibility Studies; Female; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Oxonic Acid; Tegafur; Treatment Outcome | 2009 |
A landmark point analysis with cytotoxic agents for advanced NSCLC.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Prognosis; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine; Young Adult | 2009 |
A phase II study of cisplatin and irinotecan as induction chemotherapy followed by accelerated hyperfractionated thoracic radiotherapy with daily low-dose carboplatin in unresectable stage III non-small cell lung cancer: JCOG 9510.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Radiotherapy Dosage; Remission Induction; Treatment Outcome | 2009 |
Phase II study of paclitaxel and irinotecan with intercalated gefitinib in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Quinazolines; Survival Rate; Treatment Outcome | 2010 |
Phase II trial of thalidomide, irinotecan and gemcitabine in chemonaive patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Thalidomide; Time Factors; Treatment Outcome | 2009 |
[Clinical study of irinotecan plus cisplatin for advanced non-small cell lung cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged | 2010 |
Efficacy and toxicity of chemoradiotherapy with carboplatin and irinotecan followed by consolidation docetaxel for unresectable stage III non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Feasibility Studies; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiotherapy Dosage; Survival Rate; Taxoids; Treatment Outcome | 2010 |
A phase I study of gemcitabine plus irinotecan for advanced NSCLC: Japan Clinical Oncology Group Trial (JCOG9904).
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Irinotecan; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Treatment Outcome | 2010 |
Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Mitomycin; Paclitaxel; Radiotherapy, Adjuvant; Vindesine | 2010 |
A randomized phase II study of a combination of docetaxel and S-1 versus docetaxel monotherapy in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy: results of Okayama Lung Cancer Study Group (OLCSG) Trial 0503.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Drug Combinations; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Salvage Therapy; Survival Rate; Taxoids; Tegafur; Treatment Outcome | 2010 |
A phase II study of cisplatin and irinotecan as induction chemotherapy followed by concomitant thoracic radiotherapy with weekly low-dose irinotecan in unresectable, stage III, non-small cell lung cancer: JCOG 9706.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Esophagitis; Female; Humans; Incidence; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pneumonia; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Remission Induction; Severity of Illness Index | 2011 |
Phase II study of nedaplatin and irinotecan with concurrent thoracic radiotherapy in patients with locally advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Irinotecan; Lung Neoplasms; Male; Organoplatinum Compounds; Recurrence | 2010 |
Randomized phase II trial of irinotecan with paclitaxel or gemcitabine for non-small cell lung cancer: association of UGT1A1*6 and UGT1A1*27 with severe neutropenia.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasm Staging; Neutropenia; Paclitaxel; Polymorphism, Genetic; Risk Factors; Survival Rate; Treatment Outcome | 2011 |
A phase I study of S-1 and irinotecan combination therapy in previously treated advanced non-small cell lung cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Tegafur | 2011 |
Phase II trial of irinotecan plus nedaplatin (INP) in treating patients with extensive stage small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome | 2011 |
Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Quinazolines; Treatment Outcome | 2011 |
Phase II study of irinotecan plus S-1 combination for previously untreated advanced non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0601.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Drug Combinations; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Tegafur | 2011 |
Phase II study of irinotecan and amrubicin in patients with relapsed non-small cell lung cancer: Okayama Lung Cancer Study Group Trial 0402.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Salvage Therapy; Survival Rate | 2012 |
A randomized phase II study of irinotecan plus cisplatin versus irinotecan plus capecitabine with or without isosorbide-5-mononitrate in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Isosorbide Dinitrate; Lung Neoplasms; Male; Middle Aged; Nitroglycerin; Treatment Outcome | 2012 |
Phase II study of cisplatin with irinotecan as induction chemotherapy followed by chemoradiotherapy for unresectable stage III non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Disease Progression; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging | 2012 |
Phase I/II study of S-1 combined with biweekly irinotecan chemotherapy in previously treated advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Salvage Therapy; Survival Rate; Tegafur; Treatment Outcome | 2012 |
[A prospective randomized controlled clinical trial of irinotecan plus cisplatin versus gemcitabine plus cisplatin as a first-line treatment for advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Diarrhea; Disease Progression; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Remission Induction; Survival Rate; Thrombocytopenia | 2012 |
Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Docetaxel; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Phase I and pharmacokinetic study of paclitaxel and irinotecan for patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Hematologic Diseases; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 2002 |
Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Paclitaxel; Survival Analysis; Vomiting | 2002 |
Second-line chemotherapy with irinotecan and vinorelbine in stage IIIB and IV non-small-cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Vinblastine; Vinorelbine | 2002 |
Phase II study of irinotecan and carboplatin for advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Survival Rate; Treatment Outcome | 2002 |
Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Survival Rate; Treatment Outcome | 2003 |
Three-week schedule of irinotecan and cisplatin in advanced non-small cell lung cancer: a multicentre phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Treatment Outcome | 2003 |
[A phase I study of gemcitabine and irinotecan as second line treatment for advanced non-small cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Thrombocytopenia | 2003 |
Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Diarrhea; Dose-Response Relationship, Drug; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Survival; Thrombocytopenia | 2003 |
Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Diarrhea; Drugs, Chinese Herbal; Female; Humans; Irinotecan; Lung Neoplasms; Male; Medicine, Kampo; Middle Aged; Treatment Outcome | 2003 |
Phase I/II study of escalating doses of nedaplatin in combination with irinotecan for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Survival Rate | 2003 |
Phase II study of irinotecan and ifosfamide in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2003 |
Phase II study of exatecan mesylate (DX-8951f) as first line therapy for advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Finland; Germany; Humans; Infusions, Intravenous; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Survival Analysis; Treatment Outcome; United Kingdom | 2003 |
Irinotecan and carboplatin in metastatic or recurrent non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Survival Analysis; Treatment Outcome | 2003 |
Phase II study of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with stage IIIb and IV non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Recombinant Proteins; Survival Rate | 2003 |
Biweekly docetaxel-irinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Recombinant Proteins; Taxoids | 2004 |
Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Confidence Intervals; Docetaxel; Drug Administration Schedule; Female; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Polymorphism, Genetic; Proportional Hazards Models; Survival Analysis; Taxoids | 2003 |
Influence of clinical parameters on quality of life during chemotherapy in patients with advanced non-small cell lung cancer: application of a general linear model.
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Diarrhea; Drug Administration Schedule; Female; Humans; Irinotecan; Linear Models; Lung Neoplasms; Male; Middle Aged; Nausea; Quality of Life; Vindesine; Vomiting, Anticipatory | 2003 |
A Phase II study of weekly irinotecan and capecitabine in patients with previously treated non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Salvage Therapy; Survival Rate; Treatment Outcome | 2003 |
Randomised phase II study of docetaxel/cisplatin vs docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group Study (WJTOG9803).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Diarrhea; Docetaxel; Female; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Survival Analysis; Taxoids; Vomiting | 2004 |
Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids; Treatment Outcome | 2004 |
[Prospective randomized study of HMVP, MVP, and HVP regimens in treatment of advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mitomycin; Prospective Studies; Vindesine | 2004 |
Dose escalation study of paclitaxel in combination with fixed-dose irinotecan in patients with advanced non-small cell lung cancer (JCOG 9807).
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Incidence; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pneumonia; Treatment Outcome | 2004 |
A phase I study and pharmacokinetics of irinotecan (CPT-11) and paclitaxel in patients with advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel | 2004 |
Phase I study of docetaxel and irinotecan in patients with advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Docetaxel; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Taxoids | 2004 |
Irinotecan and docetaxel as first line chemotherapy in patients with stage IIIB/IV non-small cell lung cancer--experience from a prematurely closed phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Taxoids | 2004 |
Adjusting for differential proportions of second-line treatment in cancer clinical trials. Part II: an application in a clinical trial of unresectable non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Female; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged | 2004 |
Cetuximab: an IgG(1) monoclonal antibody for the treatment of epidermal growth factor receptor-expressing tumours.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Colorectal Neoplasms; Drug Administration Schedule; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Gene Expression; Genes, erbB-1; Head and Neck Neoplasms; Humans; Immunoglobulin G; Irinotecan; Lung Neoplasms; Male; Mice | 2004 |
Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Quality of Life; Survival Analysis; Taxoids | 2004 |
Irinotecan in advanced lung cancer: focus on North American trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Deoxycytidine; Enzyme Inhibitors; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; North America; Radiotherapy, Adjuvant; Ribonucleotide Reductases; Survival Rate; Taxoids; Topoisomerase I Inhibitors; Vindesine | 2004 |
Phase II study of irinotecan combined with carboplatin in previously untreated non-small-cell lung cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Rate; Thrombocytopenia | 2004 |
Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy, Conformal; Remission Induction; Survival Analysis; Treatment Outcome | 2004 |
A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Taxoids | 2005 |
Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
Irinotecan and carboplatin in metastatic or recurrent NSCLC: an update.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Survival Analysis; Treatment Outcome | 2004 |
Phase I study of combination chemotherapy with gemcitabine and irinotecan for non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged | 2005 |
Phase II study of nedaplatin and irinotecan for elderly patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Humans; Irinotecan; Lung Neoplasms; Male; Organoplatinum Compounds; Time Factors; Treatment Outcome | 2004 |
Phase II trial of karenitecin in patients with relapsed or refractory non-small cell lung cancer (CALGB 30004).
Topics: Aged; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome | 2005 |
S-phase modulation by irinotecan: pilot studies in advanced solid tumors.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cyclin A; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Irinotecan; Male; Maximum Tolerated Dose; Respiratory Tract Neoplasms; S Phase | 2005 |
Front-line treatment of advanced non-small cell lung cancer with irinotecan and docetaxel: a multicentre phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
A phase II trial with RFS2000 (rubitecan) in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis | 2005 |
Phase I and pharmacokinetic study of docetaxel, irinotecan, and celecoxib in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase 2 Inhibitors; Docetaxel; Drug Interactions; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Pyrazoles; Sulfonamides; Taxoids | 2006 |
Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Patient Compliance; Prospective Studies; Survival Analysis | 2005 |
Front-line paclitaxel and irinotecan combination chemotherapy in advanced non-small-cell lung cancer: a phase I-II trial.
Topics: Adult; Aged; Camptothecin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate | 2005 |
Evaluation of irinotecan plus paclitaxel in patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Survival Analysis; Time Factors | 2005 |
A phase I/II trial of irinotecan-cisplatin combined with an anti-late-diarrhoeal programme to evaluate the safety and antitumour response of this combination therapy in patients with advanced non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antacids; Antidiarrheals; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cholagogues and Choleretics; Cisplatin; Diarrhea; Disease Progression; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Magnesium Oxide; Male; Maximum Tolerated Dose; Middle Aged; Sodium Bicarbonate; Survival Analysis; Ursodeoxycholic Acid | 2005 |
Phase II study of weekly irinotecan plus capecitabine for chemotherapy-naive patients with advanced nonsmall cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Probability; Prognosis; Risk Assessment; Statistics, Nonparametric; Survival Rate; Treatment Outcome | 2005 |
Same-day pegfilgrastim and chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Filgrastim; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Lung Neoplasms; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Taxoids; Vinblastine; Vinorelbine | 2005 |
Phase I study of cisplatin and irinotecan combined with concurrent hyperfractionated accelerated thoracic radiotherapy for locally advanced non-small cell lung carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Esophagitis; Female; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival Rate | 2005 |
Randomized Phase II study of two opposite administration sequences of irinotecan and cisplatin in patients with advanced nonsmall cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Sex Factors; Treatment Outcome | 2006 |
Phase II study of irinotecan and docetaxel in patients with previously treated non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 007).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Irinotecan; Italy; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival Rate; Taxoids; Treatment Outcome | 2006 |
A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Bridged-Ring Compounds; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Patient Compliance; Quality of Life; Survival Analysis; Taxoids | 2007 |
A phase II study of irinotecan plus cisplatin for patients with advanced stage IIIB or IV NSCLC previously treated with nonplatinum-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Female; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Treatment Outcome | 2006 |
Phase I and pharmacologic study of irinotecan and amrubicin in advanced non-small cell lung cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged | 2007 |
Phase II study of combination chemotherapy with gemcitabine and irinotecan in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Platinum; Survival Rate | 2006 |
Phase II study of 3-week scheduling of irinotecan in combination with cisplatin in patients with advanced nonsmall-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Survival Analysis | 2006 |
Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase Inhibitors; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Pyrazoles; Sulfonamides; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Quality of Life; Survival Rate; Vinblastine; Vinorelbine | 2007 |
Phase II study of biweekly administration of docetaxel and irinotecan in patients with refractory or relapsed advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Radiation-Sensitizing Agents; Survival Rate; Taxoids; Treatment Outcome | 2007 |
[Irinotecan plus cisplatin for the treatment of advanced non-small cell lung cancer].
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Diarrhea; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Remission Induction; Survival Rate | 2006 |
Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Dacarbazine; Disease-Free Survival; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Temozolomide | 2006 |
Phase II study of carboplatin, irinotecan, and thalidomide in patients with advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Survival Rate; Thalidomide | 2006 |
A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pharmacogenetics; Probability; Survival Analysis; Treatment Outcome | 2006 |
Triple combination chemotherapy with cisplatin, docetaxel, and irinotecan for advanced non-small cell lung cancer: a phase I/II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival Rate; Taxoids | 2007 |
Phase I study of radical thoracic radiation, weekly irinotecan, and cisplatin in locally advanced non-small cell lung carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging | 2007 |
Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; Female; Gene Frequency; Genotype; Haplotypes; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Membrane Transport Proteins; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neutropenia; Polymorphism, Genetic; Treatment Outcome | 2007 |
Irinotecan and cisplatin with concurrent split-course radiotherapy in locally advanced nonsmall-cell lung cancer: a multiinstitutional phase 2 study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiotherapy Dosage; Survival Rate; Treatment Outcome | 2007 |
Phase I study of irinotecan and gemcitabine in previously untreated patients with advanced non-small cell lung cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Treatment Outcome | 2007 |
Phase II study of weekly irinotecan and cisplatin for refractory or recurrent non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local | 2007 |
Phase I study of vinorelbine and irinotecan in previously untreated patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Camptothecin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Vinblastine; Vinorelbine | 2008 |
Phase II study of paclitaxel and irinotecan chemotherapy in patients with advanced nonsmall cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Prognosis; Survival Rate; Treatment Outcome | 2007 |
Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Genotype; Haplotypes; Humans; Irinotecan; Liver-Specific Organic Anion Transporter 1; Lung Neoplasms; Male; Middle Aged; Organic Anion Transporters; Polymorphism, Genetic; Treatment Outcome | 2008 |
Sequential chemotherapy with combination irinotecan and cisplatin followed by docetaxel for treatment-naïve patients with advanced non-small cell lung cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Follow-Up Studies; Hong Kong; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prodrugs; Radiation-Sensitizing Agents; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2007 |
Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Radiation-Sensitizing Agents; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome; Virginia | 2007 |
Phase II study of nedaplatin and irinotecan followed by gefitinib for elderly patients with unresectable non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Organoplatinum Compounds; Quinazolines | 2008 |
Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis | 2008 |
Phase II study of cisplatin combined to irinotecan administered alternatingly with docetaxel in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Docetaxel; Female; Humans; Irinotecan; Male; Middle Aged; Taxoids; Treatment Outcome | 2007 |
[A pilot study of irinotecan hydrochloride(CPT-11)and cisplatin(CDDP)combination chemotherapy for previously treated non-small cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Survival Rate | 2008 |
Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small ce
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Contraindications; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pneumonectomy; Quinazolines; Radiation-Sensitizing Agents; Radiotherapy, Conformal; Retrospective Studies; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Is irinotecan plus docetaxel useful as second-line therapy in advanced non-small cell lung cancer?
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Female; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Prospective Studies; Salvage Therapy; Survival Rate; Taxoids | 2008 |
Randomized phase 2 study of irinotecan plus cisplatin versus gemcitabine plus vinorelbine as first-line chemotherapy with second-line crossover in patients with advanced nonsmall cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cross-Over Studies; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Vinblastine; Vinorelbine | 2008 |
Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Recombinant Proteins; Treatment Outcome | 1994 |
Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Diarrhea; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Half-Life; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Recombinant Proteins; Remission Induction; Thrombocytopenia | 1994 |
Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neoplasms, Unknown Primary; Neutropenia; Recombinant Proteins; Salivary Gland Neoplasms; Stomach Neoplasms; Topotecan | 1994 |
Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatin.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Diarrhea; Drug Interactions; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Topoisomerase I Inhibitors | 1995 |
Clinical studies of irinotecan alone and in combination with cisplatin.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging | 1994 |
Phase II study of topotecan in metastatic non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Topotecan; Treatment Outcome | 1994 |
Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Diarrhea; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Vindesine | 1994 |
Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Camptothecin; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Survival Rate; Thrombocytopenia; Topotecan; Treatment Outcome | 1996 |
3-D conformal radiotherapy for lung cancer. The Washington University experience.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Feasibility Studies; Humans; Lung Neoplasms; Lymph Nodes; Missouri; Radiation Injuries; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Thorax; Topotecan | 1996 |
[Phase I study of cisplatin, ifosfamide and CPT11 with granulocyte colony-stimulating factor support in advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Male; Middle Aged; Prognosis | 1996 |
Results of a trial with topotecan dose escalation and concurrent thoracic radiation therapy for locally advanced, inoperable nonsmall cell lung cancer.
Topics: Aged; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Thorax; Topotecan | 1996 |
Phase II study of irinotecan and etoposide in patients with metastatic non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged | 1997 |
A phase I study of irinotecan and infusional cisplatin for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Diarrhea; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged | 1997 |
A phase I study of irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support in the treatment of advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Recombinant Proteins | 1997 |
Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Enzyme Inhibitors; Etoposide; Female; Hematologic Diseases; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 1997 |
A phase I clinical and pharmacologic study of a carboplatin and irinotecan regimen combined with recombinant human granulocyte-colony stimulating factor in the treatment of patients with advanced nonsmall cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Recombinant Proteins | 1998 |
Irinotecan (CPT-11) in combination with weekly administration of cisplatin (CDDP) for non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Diarrhea; Drug Administration Schedule; Female; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged | 1998 |
A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. CPT-11 Lung Cancer Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Survival Rate | 1998 |
Limited sampling model for the area under the concentration versus time curve of irinotecan and its application to a multicentric phase II trial.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Metabolic Clearance Rate; Middle Aged; Nausea; Recombinant Proteins; Reproducibility of Results; Vomiting | 1997 |
A phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome | 1998 |
[Clinical evaluation of irinotecan combined with cisplatin by divided administration in patients with untreated primary non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Safety | 1998 |
Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: a phase I study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hemoglobins; Humans; Irinotecan; Leukocyte Count; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platelet Count | 1999 |
Phase I/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiation-Sensitizing Agents; Treatment Outcome | 1999 |
A phase II study of irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Recombinant Proteins | 1999 |
Phase I study of cisplatin, ifosfamide and irinotecan with rhG-CSF support in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome | 1999 |
Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies.
Topics: Adult; Aged; Anticonvulsants; Blood Cell Count; Brain Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Glioma; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Logistic Models; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged | 1999 |
[Period of time patients with advanced non-small cell lung cancer could remain at home during CIC--therapy (cisplatin + ifosfamide + CPT-11)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Male; Middle Aged; Outpatient Clinics, Hospital; Survival Rate | 1999 |
Second-line chemotherapy with weekly cisplatin and irinotecan in patients with refractory lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Survival Analysis | 1999 |
Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging | 1999 |
[A phase II study of irinotecan combined with cisplatin in non-small cell lung cancer. CPT-11 Lung Cancer Study Group].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Survival Analysis | 2000 |
Phase I/II study of cisplatin, ifosfamide and irinotecan with rhG-CSF support in patients with stage IIIB and IV non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Male; Middle Aged; Recombinant Proteins; Survival Analysis | 2000 |
Second-line treatment of small-cell lung cancer with the camptothecin-derivative GI147211: a study of the EORTC Early Clinical Studies Group (ECSG).
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Prognosis; Salvage Therapy; Survival Rate; Treatment Outcome | 2000 |
Salvage treatment of advanced non-small-cell lung cancer previously treated with docetaxel-based front-line chemotherapy with irinotecan (CPT-11) in combination with cisplatin.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome | 2000 |
Phase I and pharmacologic study of docetaxel and irinotecan in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Disease-Free Survival; Docetaxel; Female; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Microtubules; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Treatment Outcome | 2000 |
Phase I/II trial of irinotecan, carboplatin, and paclitaxel in advanced or metastatic NSCLC.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Remission Induction; Survival Analysis | 2000 |
Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: an EORTC-ECSG phase II clinical study.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 2000 |
A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fever; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Salvage Therapy; Taxoids | 2000 |
Phase I study of carboplatin, docetaxel and irinotecan with recombinant human granulocyte colony stimulating factor support in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 2000 |
Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel | 2001 |
Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Treatment Outcome | 2001 |
Phase I study of irinotecan and cisplatin with concurrent split-course radiotherapy in unresectable and locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 2001 |
Fractionated administration of irinotecan and cisplatin for treatment of non-small-cell lung cancer: a phase II study of Okayama Lung Cancer Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Drug Synergism; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Middle Aged; Neoplasm Staging | 2001 |
A phase II trial of 9-aminocaptothecin (9-AC) as a 120-h infusion in patients with non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Rate; Time Factors; Topoisomerase I Inhibitors; Treatment Outcome | 2001 |
Dose escalation study of irinotecan combined with carboplatin for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Hematologic Diseases; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged | 2001 |
Cisplatin and irinotecan (CPT-11) as second-line treatment in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Salvage Therapy; Survival Analysis | 2001 |
Phase I/II and pharmacologic study of irinotecan and carboplatin for patients with lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Diarrhea; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Treatment Outcome | 2001 |
Preoperative induction chemotherapy with cisplatin and irinotecan for pathological N(2) non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Irinotecan; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Preoperative Care; Radiotherapy; Remission Induction; Survival Rate; Treatment Outcome | 2002 |
Weekly chemotherapy with carboplatin, docetaxel and irinotecan in advanced non-small-cell-lung cancer: a phase II study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dexamethasone; Docetaxel; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
Phase I study of carboplatin, irinotecan and docetaxel on a divided schedule with recombinant human granulocyte colony stimulating factor support in patients with stage IIIB or IV non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Recombinant Proteins; Taxoids | 2002 |
A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Evaluation; Female; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged | 1992 |
Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Evaluation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Ovarian Neoplasms; Topotecan | 1992 |
Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Diarrhea; Drug Evaluation; Esophageal Neoplasms; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Middle Aged; Pharyngeal Neoplasms | 1992 |
[Advances in lung cancer].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Combined Modality Therapy; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Vinblastine; Vinorelbine | 1992 |
Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Drug Evaluation; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged | 1991 |
145 other study(ies) available for camptothecin and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Catalytic inhibition of topoisomerase IIalpha by demethylzeylasterone, a 6-oxophenolic triterpenoid from Kokoona zeylanica.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Catalysis; DNA; DNA Topoisomerases, Type II; DNA-Binding Proteins; Electrophoresis, Agar Gel; Electrophoretic Mobility Shift Assay; Enzyme Inhibitors; Female; Glioma; Humans; Inhibitory Concentration 50; Lung Neoplasms; Methyl Green; Molecular Structure; Plants, Medicinal; Saccharomyces cerevisiae; Structure-Activity Relationship; Topoisomerase II Inhibitors; Triterpenes; Tumor Cells, Cultured | 2001 |
Discovery of 4-anilinofuro[2,3-b]quinoline derivatives as selective and orally active compounds against non-small-cell lung cancers.
Topics: Administration, Oral; Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; Mice; Mice, Nude; Mitosis; Models, Molecular; Neoplasm Transplantation; Oximes; Quinolines; Solubility; Stereoisomerism; Structure-Activity Relationship; Tissue Distribution; Topoisomerase Inhibitors; Transplantation, Heterologous | 2011 |
Targeting HER2 May Overtake Chemo, Immunotherapy in NSCLC.
Topics: Antibodies, Monoclonal, Humanized; Camptothecin; Carcinoma, Non-Small-Cell Lung; Humans; Immunoconjugates; Immunotherapy; Lung Neoplasms; Receptor, ErbB-2; Trastuzumab | 2021 |
Patritumab Deruxtecan: Paving the Way for EGFR-TKI-Resistant NSCLC.
Topics: Antibodies, Monoclonal, Humanized; Camptothecin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Protein Kinase Inhibitors | 2022 |
Trastuzumab deruxtecan shows durable activity in HER2-mutant non-small cell lung cancer.
Topics: Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Immunoconjugates; Lung Neoplasms; Receptor, ErbB-2; Trastuzumab | 2022 |
Trastuzumab Deruxtecan in Non-Small-Cell Lung Cancer.
Topics: Camptothecin; Carcinoma, Non-Small-Cell Lung; Humans; Immunoconjugates; Lung Neoplasms; Trastuzumab | 2022 |
Trastuzumab Deruxtecan in Non-Small-Cell Lung Cancer. Reply.
Topics: Camptothecin; Carcinoma, Non-Small-Cell Lung; Humans; Immunoconjugates; Lung Neoplasms; Trastuzumab | 2022 |
Trastuzumab Deruxtecan in Non-Small-Cell Lung Cancer.
Topics: Camptothecin; Carcinoma, Non-Small-Cell Lung; Humans; Immunoconjugates; Lung Neoplasms; Trastuzumab | 2022 |
FDA Gives Nod to T-DXd for HER2-Mutant NSCLC.
Topics: Antibodies, Monoclonal, Humanized; Camptothecin; Carcinoma, Non-Small-Cell Lung; Humans; Immunoconjugates; Lung Neoplasms; Receptor, ErbB-2; Trastuzumab | 2022 |
Phthalate derivative DEHP disturbs the antiproliferative effect of camptothecin in human lung cancer cells by attenuating DNA damage and activating Akt/NF-κB signaling pathway.
Topics: Camptothecin; Carcinoma, Non-Small-Cell Lung; Diethylhexyl Phthalate; Humans; Lung Neoplasms; NF-kappa B; Plasticizers; Proto-Oncogene Proteins c-akt; Signal Transduction | 2023 |
Loss of Rb1 Associated With the Onset of Acquired Resistance to Trastuzumab Deruxtecan in TP53-/HER2-Mutated Non-Small-Cell Lung Cancer: Case Series.
Topics: Camptothecin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Retinoblastoma Binding Proteins; Trastuzumab; Tumor Suppressor Protein p53; Ubiquitin-Protein Ligases | 2023 |
Poly(amidoamine) Dendrimer/Camptothecin Complex: From Synthesis to In Vitro Cancer Cell Line Studies.
Topics: Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line; Dendrimers; Humans; Lung Neoplasms | 2023 |
Metastatic
Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Immunoconjugates; Lung Neoplasms; Receptor, ErbB-2; Trastuzumab | 2023 |
Acid/GSH Dual-Responsive Endosome Escape Dual Pro-drug Micelles Targeted Synergistic Treatment for A549/ADR.
Topics: Camptothecin; Carcinoma, Non-Small-Cell Lung; Doxorubicin; Endosomes; Humans; Hydrogen-Ion Concentration; Lung Neoplasms; MCF-7 Cells; Micelles; Polyethylene Glycols; Prodrugs | 2023 |
Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial.
Topics: Camptothecin; Carcinoma, Non-Small-Cell Lung; Humans; Immunoconjugates; Lung Neoplasms; Male | 2023 |
Optimizing Dosing of Trastuzumab Deruxtecan in
Topics: Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Immunoconjugates; Lung Neoplasms; Receptor, ErbB-2; Trastuzumab | 2023 |
Molecular self-assembly of a tyroservatide-derived octapeptide and hydroxycamptothecin for enhanced therapeutic efficacy.
Topics: Animals; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Lung Neoplasms; Mice; Oligopeptides | 2021 |
Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond.
Topics: Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Immunoconjugates; Lung Neoplasms; Receptor, ErbB-2; Trastuzumab | 2021 |
Self-targeted polymersomal co-formulation of doxorubicin, camptothecin and FOXM1 aptamer for efficient treatment of non-small cell lung cancer.
Topics: Animals; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Doxorubicin; Drug Delivery Systems; Forkhead Box Protein M1; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Nanoparticles | 2021 |
Tumor-targeted SN38 inhibits growth of early stage non-small cell lung cancer (NSCLC) in a KRas/p53 transgenic mouse model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA Damage; Drug Evaluation, Preclinical; Epithelial-Mesenchymal Transition; Humans; Irinotecan; Lung Neoplasms; MAP Kinase Signaling System; Mice, Transgenic; Neoplasm Staging; Phosphorylation; Proto-Oncogene Proteins p21(ras); Resorcinols; Tumor Burden; Tumor Suppressor Protein p53 | 2017 |
Survival Outcomes According to TIMP1 and EGFR Expression in Heavily Treated Patients with Advanced Non-small Cell Lung Cancer who Received Biweekly Irinotecan Plus Bevacizumab.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Female; Gene Expression; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Mutation; Survival Analysis; Tissue Inhibitor of Metalloproteinase-1; Treatment Outcome | 2017 |
[Inhibition of autophagy initiation stage enhances camptothecin-induced apoptosis in NCI-H1975 cells].
Topics: Adenine; Apoptosis; Autophagy; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Chloroquine; Humans; Lung Neoplasms; Transforming Growth Factor beta1 | 2017 |
CT‑1042, a novel anticancer agent, exhibits effects by activating p53 and inhibiting survivin.
Topics: Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Fluorenes; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Membrane Potential, Mitochondrial; Mice; Repressor Proteins; Small Molecule Libraries; Survivin; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2018 |
Human non‑small cell lung cancer cells can be sensitized to camptothecin by modulating autophagy.
Topics: Adenine; Amino Acid Chloromethyl Ketones; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Camptothecin; Carcinoma, Non-Small-Cell Lung; Caspase Inhibitors; Cell Line, Tumor; Cell Movement; DNA Damage; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Histones; Humans; Inhibitory Concentration 50; Lung Neoplasms | 2018 |
Astragalus polysaccharide combined with 10-hydroxycamptothecin inhibits metastasis in non-small cell lung carcinoma cell lines via the MAP4K3/mTOR signaling pathway.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Astragalus Plant; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Survival; Gene Expression; Humans; Lung Neoplasms; Mitochondria; Polysaccharides; Protein Serine-Threonine Kinases; Signal Transduction; TOR Serine-Threonine Kinases | 2018 |
Selective cytotoxicity and combined effects of camptothecin or paclitaxel with sodium-R-alpha lipoate on A549 human non-small cell lung cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Epithelial Cells; Humans; Lung Neoplasms; Paclitaxel; Thioctic Acid; Tumor Cells, Cultured | 2014 |
Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data.
Topics: Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Glutamates; Guanine; Hospitalization; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Registries; Retrospective Studies; Survival Rate; Taxoids; United States; United States Department of Veterans Affairs; Vinblastine; Vinorelbine | 2014 |
Protracted dosing of the lipophilic camptothecin analogue AR-67 in non-small cell lung cancer xenografts and humans.
Topics: Adult; Animals; Biopsy, Large-Core Needle; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Humans; Lung; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasms; Organosilicon Compounds; Pilot Projects; Random Allocation; Survival Analysis; Tissue Distribution; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays | 2014 |
Knockdown of Merm1/Wbscr22 attenuates sensitivity of H460 non-small cell lung cancer cells to SN-38 and 5-FU without alteration to p53 expression levels.
Topics: Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Irinotecan; Lung Neoplasms; Methyltransferases; Reproducibility of Results; Tumor Suppressor Protein p53 | 2015 |
Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzamides; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; DNA Methylation; Drug Evaluation, Preclinical; Epigenesis, Genetic; Female; Histones; Humans; Irinotecan; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Transplantation; Pyridines | 2015 |
FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzodioxoles; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Colorectal Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Female; Gene Silencing; Humans; Indolizines; Irinotecan; Lung Neoplasms; Mice, SCID; Neoplasm Proteins; Topoisomerase Inhibitors; Treatment Outcome; Xenograft Model Antitumor Assays | 2015 |
Topoisomerase-I PS506 as a Dual Function Cancer Biomarker.
Topics: Amino Acid Sequence; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Colonic Neoplasms; DNA Topoisomerases, Type I; Female; Gene Expression; Humans; Irinotecan; Lung; Lung Neoplasms; Molecular Sequence Data; Neoplasms; Ovarian Neoplasms; Phosphorylation; Serine; Topotecan | 2015 |
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.
Topics: 4-Aminopyridine; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Carcinoma, Non-Small-Cell Lung; CDC2 Protein Kinase; Cell Cycle Checkpoints; Cell Line, Tumor; Checkpoint Kinase 1; Checkpoint Kinase 2; Cyclin-Dependent Kinases; Deoxycytidine; DNA Damage; Drug Synergism; Gemcitabine; HT29 Cells; Humans; Irinotecan; Lung Neoplasms; Lymphoma, B-Cell; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, Transgenic; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins p21(ras); Pyrazines; Xenograft Model Antitumor Assays | 2016 |
Preparation, Characterization, and In Vivo Study of 7-Ethyl-14-Aminocamptothecin-Loaded Poly(Ethylene Glycol)2000 -Poly(Lactic Acid)2000 Polymeric Micelles Against H460 Human Nonsmall Cell Lung Carcinoma.
Topics: Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Delayed-Action Preparations; Female; Hep G2 Cells; Humans; Lactic Acid; Lung; Lung Neoplasms; Mice, Nude; Micelles; Polyesters; Polyethylene Glycols; Polymers | 2015 |
Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; ErbB Receptors; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Pemetrexed; Prognosis; Retrospective Studies; Survival Rate; Vinblastine; Vinorelbine | 2016 |
Efficacy and safety of extended use of platinum-based doublet chemotherapy plus endostatin in patients with advanced nonsmall cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Endostatins; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Pemetrexed; Retrospective Studies; Survival Rate; Treatment Outcome | 2016 |
A Quinone-Containing Compound Enhances Camptothecin-Induced Apoptosis of Lung Cancer Through Modulating Endogenous ROS and ERK Signaling.
Topics: A549 Cells; Acetylcysteine; Antineoplastic Agents; Apoptosis; Benzoquinones; Camptothecin; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mitochondria; Putrescine; Reactive Oxygen Species | 2017 |
An Acetamide Derivative as a Camptothecin Sensitizer for Human Non-Small-Cell Lung Cancer Cells through Increased Oxidative Stress and JNK Activation.
Topics: A549 Cells; Acetamides; Antineoplastic Agents; Apoptosis; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Synergism; Humans; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; Membrane Potential, Mitochondrial; Microscopy, Fluorescence; Mitochondria; Oxidative Stress; Reactive Oxygen Species; S Phase Cell Cycle Checkpoints | 2016 |
The role of thymidylate synthase in non-small cell lung cancer treated with pemetrexed continuation maintenance therapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Cisplatin; Disease Progression; Female; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Phenylurea Compounds; Prognosis; Pyridines; Retrospective Studies; Survival Rate; Thymidylate Synthase | 2017 |
Time-Series Modeling and Simulation for Comparative Cost-Effective Analysis in Cancer Chemotherapy: An Application to Platinum-Based Regimens for Advanced Non-small Cell Lung Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Computer Simulation; Cost-Benefit Analysis; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Models, Economic; Paclitaxel; Quality-Adjusted Life Years; Vinblastine; Vinorelbine | 2017 |
[Report from the 44th Congress of the American Society of Clinical Oncology].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Lung Neoplasms; Mass Screening; Medical Oncology; Neoplasms; Organoplatinum Compounds; Societies, Medical | 2008 |
Cytotoxic effects of camptothecin and cisplatin combined with tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) in a model of primary culture of non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cells, Cultured; Cisplatin; Combined Modality Therapy; Humans; Immunoblotting; Immunoenzyme Techniques; Lung Neoplasms; Receptors, TNF-Related Apoptosis-Inducing Ligand; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; TNF-Related Apoptosis-Inducing Ligand | 2009 |
Comparison of chemotherapy for unresectable pulmonary high-grade non-small cell neuroendocrine carcinoma and small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Drug Therapy, Combination; Female; Humans; Immunohistochemistry; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Platinum Compounds; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2010 |
P53 and p38 MAPK pathways are involved in MONCPT-induced cell cycle G2/M arrest in human non-small cell lung cancer A549.
Topics: Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Division; Cell Line, Tumor; Cell Proliferation; G2 Phase; Humans; Lung Neoplasms; Models, Biological; Oncogene Protein v-akt; p38 Mitogen-Activated Protein Kinases; RNA, Small Interfering; Signal Transduction; Tumor Suppressor Protein p53 | 2010 |
[Assessment of total bilirubin or SN-38/SN-38G ratio as a predictor of severe irinotecan toxicity].
Topics: Aged; Antineoplastic Agents, Phytogenic; Bilirubin; Camptothecin; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Female; Glucuronates; Humans; Individuality; Irinotecan; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma | 2009 |
Association of SUMO1 and UBC9 genotypes with tumor response in non-small-cell lung cancer treated with irinotecan-based chemotherapy.
Topics: Adult; Aged; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Genotype; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; SUMO-1 Protein; Survival Analysis; Ubiquitin-Conjugating Enzymes; Up-Regulation | 2010 |
Synergistic antitumor activity of the SN-38-incorporating polymeric micelles NK012 with S-1 in a mouse model of non-small cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Drug Delivery Systems; Drug Synergism; Female; Humans; Intestinal Mucosa; Irinotecan; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Micelles; Oxonic Acid; RNA, Messenger; Tegafur; Thymidylate Synthase; Xenograft Model Antitumor Assays | 2010 |
Triplet chemotherapy with cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Signet Ring Cell; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Follow-Up Studies; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids | 2010 |
The UGT1A1*28 genotype and the toxicity of low-dose irinotecan in patients with advanced lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Genotype; Glucuronosyltransferase; Heterozygote; Homozygote; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Polymorphism, Genetic; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma | 2010 |
Enhancement of radiation-induced DNA damage and inhibition of its repair by a novel camptothecin analog.
Topics: Apoptosis; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Combined Modality Therapy; DNA Damage; DNA Repair; DNA Topoisomerases, Type I; DNA, Neoplasm; Histones; Humans; Lung Neoplasms; Phosphorylation; Radiation-Sensitizing Agents; Topoisomerase I Inhibitors | 2010 |
Simvastatin enhances irinotecan-induced apoptosis in human non-small cell lung cancer cells by inhibition of proteasome activity.
Topics: Apoptosis; Benzimidazoles; Blotting, Western; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; Flow Cytometry; Humans; I-kappa B Proteins; Irinotecan; Lung Neoplasms; NF-kappa B; NF-KappaB Inhibitor alpha; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Simvastatin; Staining and Labeling; Substrate Specificity | 2011 |
MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.
Topics: Allosteric Regulation; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Heterocyclic Compounds, 3-Ring; Humans; Lapatinib; Lung Neoplasms; Mice; Molecular Structure; Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines; Xenograft Model Antitumor Assays | 2010 |
Genotoxic effects of irinotecan combined with the novel platinum(II) complexes in human cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Comet Assay; DNA Repair; Humans; Irinotecan; Lung Neoplasms; Mutagens; Organoplatinum Compounds | 2010 |
[mRNA quantification. The next challenge in routine diagnostics].
Topics: Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Drug Delivery Systems; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Molecular Diagnostic Techniques; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Prognosis; RNA, Messenger; Survival Rate; Thymidylate Synthase | 2010 |
Expression of phosphorylated Akt in patients with small cell carcinoma of the lung indicates good prognosis.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Immunohistochemistry; Irinotecan; Kaplan-Meier Estimate; Lung; Lung Neoplasms; Male; Middle Aged; Phosphorylation; Polymorphism, Genetic; Prognosis; Proto-Oncogene Proteins c-akt; Small Cell Lung Carcinoma; Treatment Outcome | 2010 |
Induction chemoradiation therapy with cisplatin plus irinotecan followed by surgical resection for superior sulcus tumor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Pneumonectomy; Radiotherapy, Adjuvant; Retrospective Studies; Treatment Outcome | 2010 |
A retrospective analysis of non-platinum-based first- and second-line chemotherapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Piperidines; Quinazolines; Retrospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Topoisomerase I inhibitor SN-38 effectively attenuates growth of human non-small cell lung cancer cell lines in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Camptothecin; Carcinoma, Lewis Lung; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Female; Humans; Irinotecan; Lung Neoplasms; Membrane Potential, Mitochondrial; Mice; Mice, Inbred C57BL; Poly(ADP-ribose) Polymerases; Topoisomerase I Inhibitors | 2011 |
Establishment of pemetrexed-resistant non-small cell lung cancer cell lines.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Fluorouracil; Folic Acid Antagonists; Gene Expression; Glutamates; Guanine; Humans; Immunoblotting; Irinotecan; Lung Neoplasms; Pemetrexed; Phosphoribosylglycinamide Formyltransferase; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Tetrahydrofolate Dehydrogenase; Thymidylate Synthase; Vinblastine; Vinorelbine | 2011 |
Post-marketing surveillance (PMS) of all patients treated with irinotecan in Japan: clinical experience and ADR profile of 13,935 patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Genital Neoplasms, Female; Glucuronosyltransferase; Humans; Incidence; Infusions, Intravenous; Irinotecan; Japan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasms; Patient Selection; Polymorphism, Genetic; Product Surveillance, Postmarketing; Risk Assessment; Risk Factors; Surveys and Questionnaires; Thrombocytopenia | 2011 |
Epidermal growth factor receptor mutations in small cell lung cancer patients who received surgical resection in China.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; China; Combined Modality Therapy; Cranial Irradiation; Docetaxel; Endostatins; Exons; Female; Genes, erbB-1; Humans; Incidental Findings; Irinotecan; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasms, Multiple Primary; Pneumonectomy; Recombinant Proteins; Smoking; Taxoids; Young Adult | 2012 |
SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Cytokines; DNA Methylation; DNA Topoisomerases, Type I; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Prognosis; Promoter Regions, Genetic; RNA Interference; RNA, Small Interfering; Sulfatases; Sulfotransferases; Topoisomerase I Inhibitors; Topotecan; Ubiquitins | 2012 |
Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Taxoids; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
HADHA is a potential predictor of response to platinum-based chemotherapy for lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Electrophoresis, Gel, Two-Dimensional; Etoposide; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Mitochondrial Trifunctional Protein; Mitochondrial Trifunctional Protein, alpha Subunit; Multienzyme Complexes; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Small Cell Lung Carcinoma; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tumor Cells, Cultured | 2011 |
A genome-wide association study for irinotecan-related severe toxicities in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Female; Genome-Wide Association Study; Genotype; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Polymorphism, Single Nucleotide; Prospective Studies | 2013 |
MET increases the sensitivity of gefitinib-resistant cells to SN-38, an active metabolite of irinotecan, by up-regulating the topoisomerase I activity.
Topics: Antineoplastic Agents; Blotting, Western; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Gefitinib; Humans; In Situ Hybridization, Fluorescence; Irinotecan; Lung Neoplasms; Proto-Oncogene Proteins c-met; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 2012 |
Induction chemoradiotherapy is superior to induction chemotherapy for the survival of non-small-cell lung cancer patients with pathological mediastinal lymph node metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Docetaxel; Female; Humans; Induction Chemotherapy; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Pneumonectomy; Proportional Hazards Models; Radiation Dosage; Risk Factors; Taxoids; Time Factors; Treatment Outcome | 2012 |
Is there still a role for mitomycin-based combination chemotherapy in treating patients with nonsmall cell lung cancer? A single institution experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Mitomycin; Retrospective Studies | 2013 |
The modulatory effect of melatonin on genotoxicity of irinotecan in healthy human lymphocytes and cancer cells.
Topics: Adenocarcinoma; Adult; Antimutagenic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; DNA Damage; DNA Repair; Drug Screening Assays, Antitumor; Female; Humans; Irinotecan; Lung Neoplasms; Lymphocytes; Melatonin; Young Adult | 2013 |
Pleural tuberculosis following lung cancer chemotherapy: a report of two cases proven pathologically by pleural biopsy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antitubercular Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Small Cell Lung Carcinoma; Tuberculosis, Pleural | 2013 |
[A case-control study of prevention of irinotecan-induced diarrhea: the reducing side effects of irinotecan by oral alkalization combined with control of defecation].
Topics: Administration, Oral; Antacids; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Defecation; Diarrhea; Female; Humans; Irinotecan; Lung Neoplasms; Magnesium Oxide; Male; Middle Aged; Sodium Bicarbonate; Ursodeoxycholic Acid | 2002 |
Dose-escalation study of weekly irinotecan and daily carboplatin with concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Thorax; Treatment Failure | 2002 |
Dramatic effect of ZD1839 ('Iressa') in a patient with advanced non-small-cell lung cancer and poor performance status.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Enzyme Inhibitors; Epidermal Growth Factor; Female; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Middle Aged; Neoplasm Staging; Paclitaxel; Protein-Tyrosine Kinases; Quinazolines; Salvage Therapy; Taxoids; Treatment Outcome | 2003 |
Antiangiogenic effects of the novel camptothecin ST1481 (gimatecan) in human tumor xenografts.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasms, Experimental; Transplantation, Heterologous; Tumor Cells, Cultured | 2003 |
Ex vivo analysis of topotecan: advancing the application of laboratory-based clinical therapeutics.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; In Vitro Techniques; Irinotecan; Lethal Dose 50; Lung Neoplasms; Male; Neoplasms; Prostatic Neoplasms; Topotecan; Tumor Cells, Cultured | 2003 |
Activity of weekly irinotecan (CPT-11) in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes.
Topics: Adult; Aged; Camptothecin; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Irinotecan; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Platinum; Prospective Studies; Taxoids | 2003 |
Enhancement of in vivo antitumor activity of classical anticancer agents by combination with the new, glutathione-interacting DNA minor groove-binder, brostallicin.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Colonic Neoplasms; DNA; Doxorubicin; Female; Glutathione; Glutathione Transferase; Guanidines; Irinotecan; Leukemia L1210; Lung Neoplasms; Mice; Mice, Inbred DBA; Mice, Nude; Pyrroles; Transplantation, Heterologous | 2003 |
Camptothecin-induced apoptosis in non-small cell lung cancer is independent of cyclooxygenase expression.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Carcinoma, Non-Small-Cell Lung; Indomethacin; Isoenzymes; Lung Neoplasms; Prostaglandin-Endoperoxide Synthases; Prostaglandins | 2003 |
Two new drugs for colon cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; Humans; Irinotecan; Lung Neoplasms; Pancreatic Neoplasms | 2004 |
The effect of DB-67, a lipophilic camptothecin derivative, on topoisomerase I levels in non-small-cell lung cancer cells.
Topics: Camptothecin; Carcinoma, Non-Small-Cell Lung; DNA Topoisomerases, Type I; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; Organosilicon Compounds; Time Factors | 2004 |
Development of a chemoresistant orthotopic human nonsmall cell lung carcinoma model in nude mice: analyses of tumor heterogenity in relation to the immunohistochemical levels of expression of cyclooxygenase-2, ornithine decarboxylase, lung-related resista
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cyclooxygenase 2; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Glutathione S-Transferase pi; Glutathione Transferase; Humans; Intramolecular Oxidoreductases; Irinotecan; Isoenzymes; Liver Neoplasms; Lung Neoplasms; Membrane Proteins; Mice; Mice, Nude; Neoplasm Proteins; Organoplatinum Compounds; Ornithine Decarboxylase; Oxaliplatin; Paclitaxel; Prostaglandin-E Synthases; Prostaglandin-Endoperoxide Synthases; Survival Rate; Transplantation, Heterologous; Vault Ribonucleoprotein Particles | 2004 |
GSTP1 affects chemoresistance against camptothecin in human lung adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Down-Regulation; Drug Resistance, Neoplasm; Glutathione Transferase; Humans; Lung Neoplasms; Necrosis | 2004 |
[Clinical pathway based on evidence-based medicine (EBM) for chemotherapy for lung cancer].
Topics: Acute Kidney Injury; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Critical Pathways; Etoposide; Evidence-Based Medicine; Female; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Vomiting | 2004 |
Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Caffeine; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; CDC2 Protein Kinase; Cell Division; Cell Line, Tumor; Cellular Senescence; G2 Phase; Humans; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Randomized Controlled Trials as Topic; Research Support as Topic; RNA, Small Interfering; Transcription, Genetic; Tumor Suppressor Protein p53 | 2005 |
The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Cisplatin; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Paclitaxel; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; Thymidylate Synthase | 2005 |
Analysis of incomplete quality of life data in advanced stage cancer: a practical application of multiple imputation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Female; Humans; Irinotecan; Linear Models; Male; Middle Aged; Neoplasm Staging; Psychometrics; Quality of Life; Randomized Controlled Trials as Topic; Reproducibility of Results; Selection Bias; Surveys and Questionnaires; Vindesine | 2005 |
[Surgical treatment for locally advanced lung cancer; therapeutic response of induction chemotherapy and postoperative chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pneumonectomy; Postoperative Period; Survival Rate | 2005 |
A slow disengagement from platinum-based chemotherapy for patients with advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Administration Schedule; Humans; Irinotecan; Lung Neoplasms; Maximum Tolerated Dose; Neutropenia; Paclitaxel; Platinum; Survival Rate; Time Factors | 2005 |
BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.
Topics: Adenosine Triphosphatases; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Western; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression; Humans; Irinotecan; Lung Neoplasms; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spectrometry, Fluorescence; Topoisomerase I Inhibitors; Topotecan | 2006 |
Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models.
Topics: Animals; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Cyclodextrins; Disease Models, Animal; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Nanotechnology; Pancreatic Neoplasms; Polymers; Sarcoma, Ewing; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2006 |
Role of ABCG2 as a biomarker for predicting resistance to CPT-11/SN-38 in lung cancer.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biomarkers, Tumor; Blotting, Western; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression; Humans; Irinotecan; Lung Neoplasms; Neoplasm Proteins; Reverse Transcriptase Polymerase Chain Reaction | 2006 |
Irinogenetics: what is the right star?
Topics: Alleles; Antineoplastic Agents, Phytogenic; Asian People; Camptothecin; Carcinoma, Non-Small-Cell Lung; DNA Topoisomerases, Type I; Drug-Related Side Effects and Adverse Reactions; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Topoisomerase I Inhibitors | 2006 |
Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose-Response Relationship, Drug; Female; Glucuronosyltransferase; Humans; Irinotecan; Korea; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pharmacogenetics; Polymorphism, Genetic; Predictive Value of Tests; Survival Analysis; Treatment Outcome | 2006 |
Potent antitumor activity of 10-methoxy-9-nitrocamptothecin.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Survival; Humans; Lung Neoplasms; Male; Mice; Prostatic Neoplasms; Transplantation, Heterologous | 2006 |
Effects of different combinations of gefitinib and irinotecan in lung cancer cell lines expressing wild or deletional EGFR.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Gefitinib; Humans; Immunohistochemistry; Irinotecan; Lung Neoplasms; Mice; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Sequence Deletion; Survival Rate; Tumor Cells, Cultured | 2006 |
[From ASCO and WCLC 2005 to clinical practice: "conventional" treatments].
Topics: Administration, Oral; Age Factors; Aged; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Etoposide; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Lung; Lung Neoplasms; Mediastinoscopy; Meta-Analysis as Topic; Middle Aged; Neoplasm Staging; Palliative Care; Pneumonectomy; Radiotherapy Dosage; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Taxoids; Time Factors; Topotecan | 2006 |
Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bridged-Ring Compounds; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Deoxycytidine; Disease Progression; Docetaxel; Female; Fibrin Fibrinogen Degradation Products; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Patient Compliance; Predictive Value of Tests; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine | 2006 |
[Lung cancer with bone metastasis].
Topics: Analgesics; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Diphosphonates; Docetaxel; Drug Administration Schedule; Etoposide; Fractures, Bone; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Pain, Intractable; Prognosis; Quinazolines; Radiotherapy Dosage; Taxoids | 2006 |
Irinotecan-cisplatin interactions assessed in cell-based screening assays: cytotoxicity, drug accumulation and DNA adduct formation in an NSCLC cell line.
Topics: Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Cisplatin; DNA Adducts; DNA Damage; Drug Evaluation, Preclinical; Humans; Hydrogen-Ion Concentration; Inhibitory Concentration 50; Irinotecan; Lactones; Lung Neoplasms; Time Factors | 2007 |
Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors.
Topics: Animals; Camptothecin; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Female; Irinotecan; Lung Neoplasms; Mice; Mice, Inbred BALB C; Micelles; Nanoparticles; Polyethylene Glycols; Polyglutamic Acid; Random Allocation; Tissue Distribution; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2006 |
Increased expression and activity of repair genes TDP1 and XPF in non-small cell lung cancer.
Topics: Camptothecin; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; DNA Damage; DNA Repair; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Phosphoric Diester Hydrolases | 2007 |
Dendrimer-encapsulated camptothecins: increased solubility, cellular uptake, and cellular retention affords enhanced anticancer activity in vitro.
Topics: Antineoplastic Agents, Phytogenic; Biocompatible Materials; Biological Transport; Brain Neoplasms; Breast Neoplasms; Camptothecin; Capsules; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Colorectal Neoplasms; Dendrimers; Female; Glioblastoma; Humans; Lung Neoplasms; Magnetic Resonance Spectroscopy; Solubility | 2006 |
Amrubicin, a novel 9-aminoanthracycline, enhances the antitumor activity of chemotherapeutic agents against human cancer cells in vitro and in vivo.
Topics: Animals; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Synergism; Female; Gefitinib; Gemcitabine; Humans; In Vitro Techniques; Irinotecan; Lung Neoplasms; Mice; Mice, Nude; Quinazolines; Random Allocation; Stomach Neoplasms; Tegafur; Trastuzumab; Uracil; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2007 |
Genome-wide cDNA microarray screening of genes related to the benefits of paclitaxel and irinotecan chemotherapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Gene Expression Regulation, Neoplastic; Genome; Humans; Interleukin-1alpha; Irinotecan; Lung Neoplasms; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Paclitaxel; Receptors, Thyrotropin-Releasing Hormone | 2006 |
Temozolomide as prophylaxis for brain metastasis in non-small cell lung cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Dacarbazine; Humans; Irinotecan; Lung Neoplasms; Temozolomide | 2006 |
[Outpatient chemotherapy for lung cancer].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gefitinib; Gemcitabine; Humans; Informed Consent; Irinotecan; Lung Neoplasms; Neutropenia; Paclitaxel; Quality of Life; Quinazolines; Taxoids; Vinblastine; Vinorelbine | 2007 |
C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells.
Topics: Acridines; Aminoacridines; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gene Amplification; Gene Expression Regulation, Neoplastic; Heterozygote; Humans; Indoles; Irinotecan; Mitoxantrone; Neoplasm Proteins; RNA, Messenger; Triazoles | 2007 |
Feasible combination chemotherapy with nedaplatin and irinotecan for patients with non-small cell lung cancer and multiple high-risk factors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Retrospective Studies; Risk Factors; Survival Analysis; Treatment Outcome | 2007 |
Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients.
Topics: Adult; Aged; Alleles; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Female; Genetic Predisposition to Disease; Glucuronosyltransferase; Humans; India; Irinotecan; Lung Neoplasms; Malaysia; Male; Middle Aged; Neoplasm Proteins; Neutropenia; Polymorphism, Genetic; Singapore; Urogenital Neoplasms | 2007 |
ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Camptothecin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Combined Modality Therapy; DNA-Binding Proteins; Docetaxel; Endonucleases; Female; Humans; Immunohistochemistry; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Predictive Value of Tests; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2008 |
Serine phosphorylation-dependent coregulation of topoisomerase I by the p14ARF tumor suppressor.
Topics: Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA Damage; DNA Topoisomerases, Type I; Gene Expression Regulation; Humans; Lung Neoplasms; Phosphorylation; Phosphoserine; Serine; Tumor Suppressor Protein p14ARF | 2007 |
Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Carcinoma, Non-Small-Cell Lung; DNA Primers; Female; Genotype; Humans; Irinotecan; Lung Neoplasms; Male; Multidrug Resistance-Associated Protein 2; Multivariate Analysis; Polymorphism, Genetic; Regression Analysis; Sex Factors; Treatment Outcome | 2009 |
Clinical trials referral resource. Clinical trials with 9-aminocamptothecin.
Topics: Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Colonic Neoplasms; Humans; Lung Neoplasms; Lymphoma; Neutropenia | 1995 |
Intracellular carboxyl esterase activity is a determinant of cellular sensitivity to the antineoplastic agent KW-2189 in cell lines resistant to cisplatin and CPT-11.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylic Ester Hydrolases; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; DNA; Drug Resistance; Drug Resistance, Multiple; Duocarmycins; Female; Humans; Irinotecan; Lung Neoplasms; Microsomes; Ovarian Neoplasms; Pyrrolidinones; Tumor Cells, Cultured | 1995 |
Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Humans; Injections, Intraperitoneal; Irinotecan; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation | 1993 |
Combination effects of cisplatin, vinorelbine and irinotecan in non-small-cell lung cancer cell lines in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Screening Assays, Antitumor; Humans; Irinotecan; Lung Neoplasms; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 1997 |
Future directions in therapeutic approaches for small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Forecasting; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Topoisomerase I Inhibitors | 1996 |
Effect of CPT-11 in combination with other anticancer agents in lung cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Survival; Drug Interactions; Drug Screening Assays, Antitumor; Humans; Irinotecan; Lung Neoplasms; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 1997 |
New drugs for the treatment of lung cancer. The Tokyo Cooperative Oncology Group.
Topics: Antineoplastic Agents; Bridged-Ring Compounds; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Organoplatinum Compounds; Taxoids; Vinca Alkaloids | 1997 |
p16INK4 expression is associated with the increased sensitivity of human non-small cell lung cancer cells to DNA topoisomerase I inhibitors.
Topics: Antineoplastic Agents, Phytogenic; Blotting, Northern; Blotting, Western; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Survival; Cyclin-Dependent Kinase Inhibitor p16; DNA Topoisomerases, Type I; Enzyme Inhibitors; Humans; Irinotecan; Lung Neoplasms; RNA, Messenger; Topoisomerase I Inhibitors; Transfection; Tumor Cells, Cultured | 1997 |
Angiocytotoxic therapy in human non-small cell lung cancer cell lines--advantage of combined effects of TNP-470 and SN-38.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Division; Cyclohexanes; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Irinotecan; Lung Neoplasms; O-(Chloroacetylcarbamoyl)fumagillol; Sesquiterpenes; Tumor Cells, Cultured | 1998 |
Determinants of CPT-11 and SN-38 activities in human lung cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylic Ester Hydrolases; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Division; DNA Topoisomerases, Type I; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Irinotecan; Lung Neoplasms; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1998 |
Dose-finding study of irinotecan and cisplatin plus concurrent radiotherapy for unresectable stage III non-small-cell lung cancer [seecomments].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging | 1998 |
Tumor lysis syndrome and acute renal failure after treatment of non-small-cell lung carcinoma with combination irinotecan and cisplatin.
Topics: Acute Kidney Injury; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Irinotecan; Lung Neoplasms; Tumor Lysis Syndrome | 1998 |
Mechanism of cytotoxicity of N-[2-(dimethylamino)ethyl] acridine-4-carboxamide and of its 7-chloro derivative: the roles of topoisomerases I and II.
Topics: Acridines; Amsacrine; Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Survival; DNA Damage; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Enzyme Inhibitors; Humans; Kinetics; Lung Neoplasms; Mice; Models, Chemical; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1999 |
Pre-clinical evaluation of new antineoplastic agents in NSCLC cell lines: evidence of histological subtype-dependent cytotoxicity.
Topics: Adenocarcinoma; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Division; Cell Survival; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Paclitaxel; Sensitivity and Specificity; Taxoids; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 1999 |
A brief historical review of the development of chemotherapy for the treatment of advanced non-small cell lung cancer: why we should look beyond platinum.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Therapy; Gemcitabine; History, 20th Century; Humans; Irinotecan; Lung Neoplasms; Medical Oncology; Paclitaxel; Vinblastine; Vinorelbine | 1999 |
Ectopic p16(ink4) expression enhances CPT-11-induced apoptosis through increased delay in S-phase progression in human non-small-cell-lung-cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Aspartic Acid; Camptothecin; Carcinoma, Non-Small-Cell Lung; Caspase 3; Caspase Inhibitors; Caspases; Cyclin A; Cyclin-Dependent Kinase Inhibitor p16; DNA Fragmentation; DNA, Complementary; Enzyme Activation; Gene Expression; Humans; Irinotecan; Lung Neoplasms; Protease Inhibitors; S Phase; Time Factors; Transfection; Tumor Cells, Cultured | 2000 |
[Histoculture drug response assay on non-small cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Doxorubicin; Drug Screening Assays, Antitumor; Etoposide; Female; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Mitomycin; Tumor Cells, Cultured | 2000 |
New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colonic Neoplasms; Doxorubicin; Drug Resistance, Multiple; Enzyme Inhibitors; Female; Humans; Irinotecan; Lung Neoplasms; Melanoma; Mice; Mice, Nude; Neoplasms; Ovarian Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2000 |
Roles of NF-kappaB and 26 S proteasome in apoptotic cell death induced by topoisomerase I and II poisons in human nonsmall cell lung carcinoma.
Topics: Apoptosis; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; DNA; DNA Damage; DNA-Binding Proteins; Enzyme Inhibitors; Etoposide; Humans; I-kappa B Proteins; Irinotecan; Leupeptins; Lung Neoplasms; NF-kappa B; NF-KappaB Inhibitor alpha; Paclitaxel; Peptide Hydrolases; Proteasome Endopeptidase Complex; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2001 |
Effectiveness of water soluble poly(L-glutamic acid)-camptothecin conjugate against resistant human lung cancer xenografted in nude mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Drug Combinations; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Paclitaxel; Polyglutamic Acid; Solubility; Taxoids; Xenograft Model Antitumor Assays | 2001 |
Conjugation of camptothecins to poly-(L-glutamic acid).
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Drug Carriers; Female; Humans; Lung Neoplasms; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Mice, Nude; Polyglutamic Acid; Solubility; Xenograft Model Antitumor Assays | 2000 |
NF-kappa B activation in topoisomerase I inhibitor-induced apoptotic cell death in human non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Carcinoma, Non-Small-Cell Lung; DNA-Binding Proteins; Enzyme Inhibitors; Humans; I-kappa B Proteins; Irinotecan; Leupeptins; Lung Neoplasms; NF-kappa B; NF-KappaB Inhibitor alpha; Topoisomerase I Inhibitors; Transfection; Tumor Cells, Cultured | 2000 |
In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Division; DNA Topoisomerases, Type I; Drug Synergism; Enzyme Inhibitors; Humans; Irinotecan; Lung Neoplasms; Organoplatinum Compounds; Thiazoles; Thiazolidinediones; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 2001 |
Novel cytotoxic 7-iminomethyl and 7-aminomethyl derivatives of camptothecin.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Division; Combinatorial Chemistry Techniques; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Structure-Activity Relationship; Survival Rate; Tumor Cells, Cultured | 2001 |
Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Liver Neoplasms, Experimental; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Tissue Distribution; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |
Lung cancer--time to move on from chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Etoposide; Humans; Irinotecan; Lung Neoplasms; Smoking; Survival Rate | 2002 |
The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Clone Cells; Colchicine; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Daunorubicin; DNA Damage; DNA, Neoplasm; Etoposide; Fluorouracil; Gene Expression Regulation, Neoplastic; Genes, p53; Humans; Lung Neoplasms; Models, Biological; Proline; Promoter Regions, Genetic; Protein Structure, Tertiary; Recombinant Fusion Proteins; Structure-Activity Relationship; Tetracycline; Transcription, Genetic; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2002 |
Point mutations in the topoisomerase I gene in patients with non-small cell lung cancer treated with irinotecan.
Topics: Camptothecin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; DNA Topoisomerases, Type I; DNA, Neoplasm; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Mutagenesis; Point Mutation; Polymorphism, Single-Stranded Conformational; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2002 |
Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression.
Topics: Adenocarcinoma; Antineoplastic Agents; Blotting, Northern; Blotting, Southern; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Line; Cell Survival; Cisplatin; DNA Topoisomerases, Type II; DNA, Neoplasm; Doxorubicin; Drug Screening Assays, Antitumor; Etoposide; Fluorouracil; Humans; Lung Neoplasms; Phenotype; Restriction Mapping; RNA, Neoplasm; Teniposide | 1992 |
CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 1992 |
Intracellular distribution of CPT-11 in CPT-11-resistant cells with confocal laser scanning microscopy.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Transformed; Cell Nucleus; Cytoplasm; Cytoplasmic Granules; Fluorescence; Humans; Image Processing, Computer-Assisted; Irinotecan; Lasers; Lung Neoplasms; Microscopy, Electron; Nuclear Envelope; Tumor Cells, Cultured; Ultrasonography | 1992 |
[A phase I study of weekly administration of CPT-11 in lung cancer].
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Evaluation; Female; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged | 1990 |
Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Nucleus; DNA Topoisomerases, Type I; Drug Resistance; Humans; Irinotecan; Lung Neoplasms; Tumor Cells, Cultured | 1990 |